





MOLECULAR INSIGHTS INTO NEUTRALIZATION 




CHAN KUAN RONG 
B.Science (Hons), NUS 
 
 
A THESIS SUBMITTED FOR THE DEGREE OF 
DOCTOR PHILOSOPHY 
 
NUS Graduate School for Integrative Sciences and Engineering 












I would like to express my heartfelt gratitude to Associate Professor Ooi Eng Eong for 
his patient guidance, advice and encouragement throughout my research. His 
continued support and mentorship significantly aided the progress of the project. I 
would also like to thank Professor Mariano Garcia-Blanco for his kind encouragement 
and suggestions.  
 
My sincere appreciation is extended to my thesis advisory committee, Professor Chan 
Soh Ha, Associate Professor Subhash Vasudevan and Dr. Justin Wong for the 
stimulating discussions and critical suggestions during my research. 
 
Special thanks to Tan Hwee Cheng, Summer Zhang, Eugenia Ong, Tanu Chawla, 
Ryan Wu, Dr. Brendon Hanson, Angeline Lim, Nivashini Kaliaperumal, Zhang Qian 
and Angelia Chow for providing technical assistance and support in my research. And 
not forgetting colleagues from Duke-NUS who have made this a very conducive 
environment for research. 
 
Lastly, I would like to thank my family and friends for their encouragement all these 






Table of contents  
Acknowledgements …..……………………………………………………...………….  
Table of contents …………………………….………………………….….……….…. 
Summary …....……..………………………...………….…………………...…….…... 
List of tables …………………………………………………………………………… 
List of figures ………………………………………………………………………….. 
List of abbreviations ………………………………………………………..……….… 
List of publications ……………………………………………………………………. 
Chapter 1: Introduction 
1.1 Dengue …….…………………...…………………………............................. 
1.1.1 Dengue epidemiology ………………………………………………… 
1.1.2 Clinical presentation and progression …………………………………. 
1.1.3 Relationship between disease pathogenesis and immunity ……………. 
1.2 Dengue virus structure and genome..….……………….………….………….  
1.3  Prevention and control of dengue ……………….………………………..…….. 
 1.3.1 Limitations in vector control programs………………………………... 
1.3.2  Vaccines in clinical development ……………………………………….  
Chimeric vaccines …………………………………………………..…..  























  Sub-unit vaccines and nucleic acid vaccines ………………………..… 
1.3.3  Challenges in dengue vaccine development ………………….………... 
1.4 Immune responses and their consequences to dengue infection……………… 
1.4.1 Antibody responses in protection and pathogenesis …….…...……….....  
Protective antibody responses……………………………………..….....  
Antibody responses in dengue pathogenesis ………………………..….   
1.4.2 T-cell responses in protection and pathogenesis ……………………….. 
Protective T-cell responses ……………………………..….......……….  
  T-cell responses in dengue pathogenesis …………...……………..….... 
            1.4.3 Cytokine responses involved in pathogenesis …………..……….……... 
1.5  Molecular insights of Dengue infection ……..…………………………….…..  
1.5.1  Dengue life cycle ……………….………….………………….………..  
1.5.2 Subversion of innate immunity to establish infection in monocytes…….  
1.6 Molecular insights of neutralization and enhancement of DENV infection .…... 
1.6.1 The role of FcγR DENV neutralization …………………………….… 
 1.6.2 The role of FcγR in ADE of dengue infection ………………………...  
1.6.3 Does ADE of DENV infection suppress innate immune responses? ....... 























Chapter 2: Methods 
2.1 Cells …………………..………….……………...……………………….......… 
2.2 THP-1 subclones …………….…….…….……...……….……………….....….. 
2.3 Antibodies …….……………….…….………...……………….......................... 
2.4 Human sera…………….………………...……………….…………….………..  
2.5 Viruses …….……………….…………...…………………………………….....  
2.6 Affinity measurements by indirect ELISA .…………….….…….………........... 
2.7 Plaque assay …….……………………….……………………………...…........  
2.8 Plaque reduction neutralization test……….…….…………...………………….  
2.9 Virus infection in THP-1 cells  ..…………….………...…………..…….….......  
2.10 Real-time PCR …………….….……………...……………..……….………….  
2.11 Fluorescent labeling of viruses …………………….....………….………......… 
2.12 Visualization and quantification of DiD-virus uptake ………….……………...  
2.13 Sucrose gradient analysis of DENV immune complex sizes …………….……. 
2.14 Western blot ………….………………………….……………………..………. 
2.15 Immunoprecipitation ……….…...…………………………………………........ 
2.16 siRNA transfection of THP-1 and K562 .…………….….…….…...................... 
2.17 Overexpression in THP-1..……………..……...………….………………..........  























2.19 Assessing surface monocytic marker expression  ...……………..………….....  
2.20 Microarray analysis…….….……………...……….……….…….…..…….…. 
2.21 Interferon and drug treatment ……………………........………….…..........….. 
2.22 Co-immunoprecipitation ………….…….…………………………......………  
2.23 ELISA to assess LILRB1 binding to DENV…………………………………… 
2.24 Statistical analysis …………….………………………………………..……… 
 
Chapter 3: Results 
3.1 Early interactions in antibody-mediated neutralization of dengue virus  
3.1.1 Homologous DENV serotypes are neutralized despite FcγR-mediated 
uptake but heterologous DENV serotypes are neutralized only when 
FcγR-mediated uptake is inhibted………………….…………….. 
3.1.2 Increasing antibody concentrations inhibits FcγR-mediated uptake of 
immune complexes ……………………………………………………. 
3.1.3 Size of DENV immune complex is dependent on the concentration of 
antibody.………………………………………………………………... 
3.1.4 Aggregation of DENV enables antibodies to cross-link the inhibitory 
FcγRIIB.…………………………….…………………………………... 
3.1.5 Dengue neutralization in the presence of phagocytosis distinguishes 
serotype-specific from cross-neutralizing antibodies with better 






































3.2 The use of FcγR in DENV neutralization  
3.2.1 FcγRI ligation is required for uptake of neutralized DENV immune 
complexes……………………………………………………………….. 
 3.2.2 FcγR-mediated phagocytosis following FcγRIIB knockdown…………. 
3.2.3 Preferential engagement of FcγRI in monocytes results in 
neutralization of DENV immune complexes………………………….... 
3.3 Regulators of FcγR-signalling in antibody-dependent enhancement of dengue 
infection  
3.3.1 Isolation of two THP-1 subclones with increased uptake of dengue 
immune complexes……………………………………………………... 
3.3.2 Two subclones of THP-1 with differential susceptibility to antibody-
dependent enhancement of dengue infection………………………..…. 
3.3.3 IFN signaling pathway contributes minimally to ISG induction…….… 
3.3.4 ISG induction following ADE of DENV infection is Syk-dependent….. 
3.3.5 ISG induction following ADE of DENV infection can be attenuated by 
increased SHP-1 phosphorylation……………………………………… 
3.3.6 Antibody opsonised DENV co-ligates LILRB1 with activating FcR 







































Chapter 4: Discussion 
4.1 Preface………………………………………………………………………...... 
4.2 Viral aggregates co-ligate inhibitory receptor FcγRIIB to inhibit uptake of 
dengue immune complexes…………………………………………………... 
4.3 Assessment of FcγR-mediated phagocytosis to distinguish protective humoral 
immunity from cross-reactive immune response………………………….…… 
4.4 Preferential engagement of FcγRI during dengue neutralization results in 
uptake and neutralization of dengue immune complexes………………………. 
4.5 LILRB1 in ADE of dengue infection……………………………………..…….. 

































Dengue virus (DENV) continues to put billions at risk of life-threatening disease 
annually and is the most prevalent mosquito-borne viral disease. However, no 
licensed dengue vaccine or drug is currently available. The underlying problem 
resides in the humoral response to DENV where immunity generated protects only 
against the serotype that caused the infection. On the other hand, cross-protection 
against the other three heterologous DENV serotypes is only transient, lasting for 2-3 
months. Moreover, subsequent infections with a different DENV serotype may result 
in increased risk of dengue haemorrhagic fever or dengue shock syndrome. One of the 
leading hypotheses to explain for this increased viraemia and disease severity during 
secondary infection is antibody-dependent enhancement (ADE), where non-
neutralizing antibodies or waning antibody titers can form dengue immune complexes 
which interact with fragment crystallisable receptors (FcγR) expressed in monocytes 
to result in enhanced uptake and infection. Hence, defining the determinants of 
successful virus neutralization and enhancement of dengue infection would be 
important in the design of an effective dengue vaccine that protects against all four 
DENV serotypes while minimizing the risk of ADE of DENV infection. Using 
fluorescent labelled DENV, we examined the early intracellular events of antibody-
opsonized DENV following interaction with human acute monocytic leukemia cells 
(THP-1) to understand how virus-antibody complexes are neutralized in human 
monocytes. We found that at neutralizing antibody concentrations, antibody 
concentration affects the size of the immune complexes formed, which results in the 
co-ligation of different FcγR. Larger immune complexes appear to cross-link FcγRIIB, 
which recruits phosphatidylinositol 3,4,5-trisphosphate 5 phosphatase-1 (SHIP-1) and 





Phagocytosis was restored when the antibody concentration was reduced, as smaller 
immune complex cross-linked activating FcγR. While serotype-specific antibodies 
can neutralize in the presence of FcγR-mediated phagocytosis, DENV immune 
complexes formed with heterologous antibodies appear to neutralize only at levels 
where phagocytosis is inhibited. In addition, we observed that when DENV is in 
complex with serotype-specific antibodies at lower antibody concentrations, uptake 
and neutralization is mediated by preferential engagement of FcγRI, through 
clustering of this receptor on the plasma membrane.  
 As only a minor subset of THP-1 show uptake of DENV immune complexes, 
even when opsonized with enhancing concentration of antibody, we hypothesized that 
the THP-1 cell line is genetically heterogeneous, either because of serial passages in 
culture or through genomic instability as a consequence of its aneuploidy.  By limiting 
dilution of THP-1, we obtained two sub-clones that showed increased FcγR-mediated 
phagocytosis of antibody-opsonized DENV as compared to the parental THP-1 cells. 
Interestingly, these two sub-clones showed differential susceptibility to antibody-
dependent enhancement (ADE) of DENV infection. In the absence of antibodies, 
however, these subclones displayed similar infection rates. We hence used these 
subclones to investigate host factors critical for effective ADE. We show here, that 
activating FcRs in the resistant subclone directly activates spleen tyrosine kinase 
(Syk) and signal transducer and activator of transcription-1 (STAT-1) to up-regulate 
the interferon stimulated genes (ISG) that inhibit DENV replication. Conversely, 
increased susceptibility was observed in the THP-1 subclone that showed increased 
surface expression of an immunoreceptor tyrosine-based inhibition motif (ITIM)-
bearing receptor leukocyte immunoglobulin-like receptor-B1 (LILRB1). Increased 





levels of phosphorylated SHP-1, and reduced Syk and STAT-1 phosphorylation to 
suppress ISG expression. Overall, our data suggests that interaction of DENV 
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1.1 Dengue.  
1.1.1 Dengue epidemiology.  
Dengue is the most prevalent mosquito-borne viral disease globally and its 
geographical distribution is still rapidly expanding. It endangers an estimated 2.5 
billion people and represents a major, growing public health problem throughout the 
tropical world along with several subtropical countries (Figure 1-1) (Guzman et al., 
2010). There are about 50 million cases of dengue infections annually (WHO 2009) 
(Figure 1-2). Clinical manifestations of dengue range from asymptomatic infection to 
dengue fever (DF) or the more severe form of the disease, dengue haemorrhagic 
fever/dengue shock syndrome (DHF/DSS). Other rare but severe complications from 
dengue infection include internal haemorrhage and organ impairment, such as 
encephalopathy. While DF is a self-limiting febrile illness, DHF/DSS case-fatality 
rates can exceed 20% without proper treatment (WHO 2009). Despite under-reporting, 
either through a lack of systematic capture of total cases or the insensitivity of clinical 
diagnosis without laboratory diagnostic capabilities that affects many dengue endemic 
regions, the burden of dengue is estimated to be approximately 1,300 disability-
adjusted life years (DALYs) per million population (Meltzer et al., 1998), placing 
dengue among the most significant diseases of children worldwide. Dengue also 
results in substantial economic loss. Based on the distribution of costs in Singapore 
from 2000-2009, it is estimated that the economic cost for dengue is an average of 
US$41.5 million per year (Carrasco et al., 2011). 
Dengue is transmitted to humans by Aedes mosquitoes. Aedes aegypti, a 
highly domesticated mosquito, is the most efficient vector of dengue because of its 





hosts for a blood meal during a single gonotrophic cycle (Gubler, 1998, Platt et al., 
1997). The secondary vector, Aedes albopictus, is also of increasing importance in 
dengue transmission (Lambrechts et al., 2010). The spread of dengue has expanded 
across tropics and subtropics, largely explained by increased geographical distribution 
of the vector from demographical change, unplanned and uncontrolled urbanization, 
inadequate domestic water supplies and increased international travel and trade 
(Gubler and Meltzer, 1999, Gubler, 2002, Gubler, 2004, Rigau-Perez et al., 1998). 
Furthermore, more places now report all four dengue virus (DENV) serotypes 
(DENV-1-4) co-circulating at any given time, which contrasts with the observations 
made 20-30 years ago (Figure 1-3). All these factors converge in their contributions 










Figure 1-1. Countries and areas at risk of dengue transmission in 2008. Dengue is 
a growing public health problem in tropical and subtropical countries in Southeast 
Asia, the Pacific and America. Shown in red are the countries or area at risk, updated 
in 1
st
 November 2008. The contour lines of the January and July isotherms indicate 
potential geographical limits of northern and southern hemispheres for Aedes aegypti. 








Figure 1-2. Cases reported to WHO from 1955-2007. Bar charts indicate average 
annual number of dengue fever and dengue haemorrhagic fever cases reported to 
WHO. Red line depicts the number of countries reported dengue cases. Growing 










Figure 1-3. Distribution of dengue virus 1-4 in (A) 1970 and (B) 2004. Compared 
to year 1970, increased incidence of all four dengue serotypes was observed in 2004. 
Data indicates the urgent need to control the spread of all four dengue serotypes. 






1.1.2 Clinical presentation and progression. 
Classic DF is the more common symptomatic infection and presents as a self-limiting 
febrile illness. After an incubation period of about 2 to 7 days, high fever ensues, 
accompanied by headache, retro-orbital pain, myalgia, arthralgia, flushing of the face, 
rash, anorexia, abdominal pain and nausea. In convalescence, macular rash can be 
observed and most patients recover without complications about a week after disease 
onset (Simmons et al., 2012).  
A small proportion of infected individuals may progress to the more severe 
form of the disease, DHF/DSS. In DHF patients, around the time of defervescence 
(Day 3-7 of illness), signs of thrombocytopenia (platelet count ≤ 100,000/mm3), 
haemorrhagic manifestations and enhanced vascular permeability with leakage of 
intravascular fluid suddenly develops (Gubler, 1998) (Figure 1-4). When a critical 
volume of plasma is lost through leakage, cardiac output may become insufficient to 
maintain the necessary blood pressure resulting in DSS. With prolonged shock, organ 
hypoperfusion can result in progressive organ impairment, metabolic acidosis and 
disseminated intravascular coagulation (WHO 2009). In the absence of proper 
treatment, a stage of profound shock may set in, eventually resulting in death within 
12 to 36 hours after shock onset. 
As intravenous rehydration can reduce case fatality rates to less than 1% of 
severe cases, it is essential to detect those progressing from non-severe to severe 
disease early for timely intervention. This requires close monitoring of patients with 
daily haematocrit measurements. Besides DSS, severe dengue also includes internal 
hemorrhage without plasma leakage or organ impairment.  The 2009 WHO dengue 





indicators of possible development of severe dengue although this list is not 
exhaustive as some patients may still progress to severe disease without showing any 











Figure 1-4. Time course of clinical signs and symptoms of dengue. The incubation 
period before signs of symptoms develop can range from day 4 to day 7. At the time 
where viraemia start to subside, DHF/DSS patients may develop thrombocytopenia 









Figure 1-5. Criteria for dengue and severe dengue. Dengue fever cases can be 
classified as probable dengue or dengue with warning signs. The presence of warning 
signs indicates that the patients will require strict observation and medical 
intervention as these patients are likely to develop into severe dengue cases. Those 
without warning signs may, however, also develop into severe dengue cases. Severe 
dengue cases are characterised by severe plasma leakage, severe bleeding or severe 








1.1.3 Relationship between disease pathogenesis and immunity. 
The pathogenesis of severe dengue is multifactorial and is influenced by the viral 
strain, age, host genetics and prior immune status. Clinical and epidemiological 
observations provide some fundamental insights to explain disease pathogenesis and 
immunity (Mathew and Rothman, 2008). (i) Long-term protective immunity prevents 
against re-infection with the same virus serotype, but only short-lived protection to 
other virus serotypes (Sabin, 1952b, Sabin, 1950). (ii) Secondary infection with a 
virus serotype different from initial exposure typically results in ~15-80 fold 
increased risk of DHF (Thein et al., 1997) (iii) DHF is observed in infants with 
primary infections whose mothers have some DENV immunity (Simmons et al., 
2007a, Kliks et al., 1988). (iv) Rapid viral replication with high viremia seems to play 
a major role in disease severity (Libraty et al., 2002b). (v) Plasma leakage, the 
hallmark of DHF typically occurs at or near defervesence, indicating that disease 
pathogenesis is primarily mediated by host immune response (Vaughn et al., 2000, 
Vaughn et al., 1997). As the complete understanding of disease pathogenesis is 
currently hampered by the absence of a good animal model for dengue infection, our 
knowledge relies mostly on well-designed clinical studies from patients, which have 
consistently shown that immune responses to DENV infection are important 






1.2 Dengue virus structure and genome. 
DENV is a member of the Flavivirus genus of the Flaviviridae family, which includes 
other clinically important viruses such as West Nile virus (WNV), Yellow Fever 
Virus (YFV), Japanese encephalitis virus (JE) and tick-borne encephalitis virus. The 
four DENV serotypes are immunologically distinct but antigenically related, each 
sharing about 65-70% homology. The virion is 40-50nm in diameter and is composed 
of a single, positive-strand RNA genome that is packaged by virus capsid (C) protein 
and surrounded by 180 monomers of envelope (E) protein organized into 90 tightly 
packed dimers that lie flat on the surface of the viral membrane (Figure 1-6). 
Individual subunits of the E protein form three beta-barrel domains, domains I (EDI), 
II (EDII) and III (EDIII), with the hydrophobic viral fusion peptide located at the tip 
of EDII and the receptor binding sites at EDIII (Figure 1-6) (Mukhopadhyay et al., 
2005, Rey, 2003).  
The 11kb DENV genome is a single open reading frame encoding a single 
polyprotein, which is cleaved by viral and cellular proteases into structural and non-
structural mature peptides (Figure 1-7). The amino terminus of the genome encodes 
for three structural proteins (C, membrane (M), E) that constitute the virus particle. 
The other seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and 
NS5) are essential for viral RNA replication, virus assembly and modulation of the 







Figure 1-6. Arrangement of envelope subunits on the mature dengue virus 
surface. Packing of E proteins on a mature DENV. One of the rafts, containing three 
parallel dimers is highlighted. EDI, EDII and EDIII are labelled red, yellow and blue 






Figure 1-7. Structure of dengue virus envelope. Dimeric, pre-fusion conformation 
of the DENV envelope protein. One monomer of EDI, EDII and EDIII is labelled red, 
yellow and blue respectively with the fusion peptide labelled green. The other 







Figure 1-8. Flavivirus genome and function of different components of the 
genome. The approximate 10kb open reading frame of the flavivirus encodes for the 
structural (C, M/prM and E) and non-structural coding regions (NS1, NS2A, NS2B, 
NS3, NS4A, NS4B and NS5), with the 5’ CAP and 3’ untranslated region at the ends 
of the genome. C is capsid, M/prM is membrane/pre-membrane and E is envelope. 
Following translation, the immature polyprotein precursor is post-translationally 
cleaved by proteases (indicated in triangles). Different non-structural genes are 
involved in different functions, including ribonucleic (RNA) replication, virus 








1.3 Prevention and control of dengue. 
1.3.1 Limitations in vector control programs. 
To reduce mortality rates arising from dengue endemic areas, effective prevention of 
dengue transmission is urgently needed. In the absence of a licensed vaccine or anti-
viral drug, vector control remains important for the prevention and control of dengue 
(Guzman and Kouri, 2002, Eisen et al., 2009). Dengue has been successfully 
prevented through vector control in at least three instances. The first of these was the 
Aedes aegypti eradication program directed by the Pan American Sanitary Board from 
1946 to 1970, where surveillance, constant inspection, chemical control and 
community involvement resulted in significant reduction in vector population 
(Schliessmann, 1967). The second was a national campaign to eradicate Aedes aegypti 
in Cuba in 1981, where intensive insecticidal treatment, followed by source reduction 
was successful in bringing epidemic under control in about 4 months (Kouri et al., 
1989). However, neither of these programs was sustainable due of lack of long-term 
political and financial support for national mosquito surveillance and control 
programs after the period of mosquito eradication (Gubler and Clark, 1994). The 
over-reliance of chemical control after mosquito re-infestation and “passive” 
participation from the community also resulted in the short-lived effectiveness from 
these eradication programs (Gubler, 1989). 
The third successful program was in Singapore. A vector control system based 
on entomologic surveillance and larval source reduction, together with public 
education and law enforcement, was initiated in 1970 following the emergence of 
DHF in the early 1960s. This resulted in the reduction of Aedes aegypti population 





(Figure 1-9) (Ooi et al., 2006). Despite the low vector density, the incidence of 
dengue surged during 1990s and continued till present day. The cause for this 
resurgence could be multifactorial, some of which may include lowered herd 
immunity from reduced dengue transmission in the 1970s and 1980s (Goh, 1995), a 
shift in virus transmission from a domestic to non-domestic setting (Ooi et al., 2001), 
more clinically overt infection due to adult infection and shift in surveillance 
emphasis of vector control program (Ooi et al., 2006, Yew et al., 2009). The 
experience in all 3 instances indicated that vector control alone requires extensive 
public resource and is ultimately not sustainable as a method for dengue prevention. 








Figure 1-9. Annual incidence of DF, DHF and the premises index in Singapore 
between 1966-2011. Annual incidences of DF and DHF calculated from the number 
of reported cases from 1966-2004. Annual premises index is expressed as a 
percentage of premises where A. aegypti or A. albopictus larvae are found divided by 
number of permises visited by environmental health officers. Data is acquired from 






1.3.2 Vaccines in clinical development. 
Safe and effective vaccines have been developed for flaviviruses such as yellow fever, 
Japanese encephalitis and tick-borne encephalitis viruses, which support the potential 
of a successful vaccine against dengue. However, development of a successful dengue 
vaccine has been challenging as the increasing co-circulation of four DENV serotypes 
in many endemic areas requires a tetravalent formulation to protect against all four 
DENV serotypes. Moreover, non-neutralizing or sub-neutralizing levels of antibodies 
may opsonize DENV and engage fragment crystallisable receptors (FcγR) for cellular 
entry (Daughaday et al., 1981, Halstead et al., 1983) to result in enhanced infection of 
FcγR-bearing cells, or antibody-dependent enhancement (ADE) of DENV infection 
(Figure 1-10) (See later sections of the introduction for complete discussion of this 
pathway of entry). Hence, the induction of antibody responses after vaccination have 
to be at levels high enough to protect against all four DENV serotypes while 
minimizing the risk of vaccine-induced ADE of DENV infection. The delicate 
balance between the immunogenicity and attenuation of DENV pathogenicity adds to 
this difficulty. Despite these obstacles, four types of dengue vaccines are currently in 
clinical development: chimeric live attenuated viruses, live attenuated viruses (LAV), 
sub-unit vaccines and nucleic acid-based vaccines (Webster et al., 2009, Schmitz et al., 
2011).  
Chimeric vaccines. 
The leading vaccine candidate in clinical trials is the Sanofi Pasteur’s ChimeriVax-
DENV vaccine which has recently entered phase 3 clinical testing (Coller and 
Clements, 2011). This chimeric vaccine consists of structural genes (prM and E) 





strain backbone (Figure 11) (Guy et al., 2010). Results from phase 1 and 2 have been 
positive as the vaccine was shown to be safe and immunogenic, with cell-mediated 
immunity biasing towards interferon-gamma (IFNγ) rather than tumour necrosis 
factor-alpha (TNFα) (Guy et al., 2008).  However, the major limitation of this vaccine 
is the requirement of the extended dosing schedule of 3 doses at 6 months intervals. 
This could mean that the vaccine is very likely to meet with major compliance issues. 
Moreover, it is not known if the incomplete immunity developed during the extended 
interval may result in an increased risk of developing an enhanced disease outcome in 
endemic areas. Importantly, based on a recent phase 2b trial on Thai school children, 
it was shown that the vaccine efficacy is only 30.2% against DENV-2 (Sabchareon et 
al., 2012), indicating that there is still much room for improvement.  
Live-attenuated vaccines. 
As yellow fever and Japanese encephalitis LAV are able to induce long-lasting 
immunity, this suggests that a dengue LAV can potentially stimulate long-lasting 
protective immunity to all DENV serotypes. Indeed, monovalent vaccines obtained by 
serial passaging in primary dog kidney cells show good immune responses in humans 
(Kanesa-Thasan et al., 2003). However, in tetravalent formulations, the major 
challenge has been to induce broad neutralizing antibody responses against all four 
DENV serotypes as a shift in antibody response to the better replicating DENV 
serotype could mean increased disease susceptibility to the other serotypes. For 
example, vaccinees who received tetravalent vaccines produced by Mahidol 
University and Sanofi Pasteur had only DENV-3 viraemia, suggesting that 
preferential replication of DENV-3 may have affected the efficacy of the tetravalent 
vaccine. Presently, two leading live-attenuated tetravalent formulations have been 





vaccinees experienced adverse reactions and imbalanced serological response towards 
the four DENV serotypes (Kitchener et al., 2006, Sanchez et al., 2006), possibly 
attributed to interference between dengue serotypes in tetravalent formulations 
(Anderson et al., 2011).  
 To overcome the limitations with live attenuation through serial passage in 
cell cultures, others have explored the use of recombinant technology using a well 
attenuated strain of DENV as the backbone. The Laboratory of Infectious Diseases 
(LID) at the National Institute of Allergy and Infectious Diseases (NIAID) has 
developed LAV consisting of structural genes from four DENV serotypes inserted 
into a DENV-4 backbone with 30 nucleotides deleted at the 3’ un-translated (UTR) 
region (Figure 11). The resultant vaccines, DENV1/4∆30, DENV2/4∆30, 
DENV3/4∆30 and DENV4∆30 were all shown to be attenuated (Whitehead et al., 
2003). Different tetravalent formulations of these vaccines are now in clinical testing 
and results have been promising thus far. Inviragen Inc, in collaboration with the 
Centers for Disease Control and Prevention, tapped on the DENV-2 (16681-PDK53) 
strain which was derived through serial passage in primary dog kidney cells as the 
genomic backbone. prM and E genes of DENV1, 3 and 4 replaced the DENV 2 genes 
to form chimeras that make up the rest of the tetravelant formulation (Figure 1-11). 
This vaccine, named DENVax, has also entered phase II clinical trials (Osorio et al., 
2011).  
Sub-unit vaccines and nucleic acid vaccines. 
The development of other types of vaccines aims to curb interference between 
different DENV serotypes observed in LAV formulations. However, the main 





to activate the immune system (Webster et al., 2009). Nevertheless, the DEN-80E 
from Hawaii Biotech, now acquired by Merck & Co, which is a subunit vaccine 
consisting of terminally truncated E glycoproteins from four DENV serotypes 
expressed in an insect cell expression system, has progressed to clinical trials as it is 
able to protect both mouse and non-human primate models from DENV infection 
(Coller et al., 2011). Other inactivated vaccines have also been considered, such as 
psoralen-inactivated vaccines which have been shown to be immunogenic and can 
reduce viraemia after experimental challenge in vivo (Maves et al., 2011, Maves et al., 
2010).  
DNA vaccines developed by the US Naval Medical Research Center have 
completed a phase 1 trial testing a DENV-1 prM/E DNA vaccine (Thomas, 2011). To 
improve immunogenicity and protection, different vector and adjuvant combinations 
have been considered. For example, DNA vaccines comprising of prM-E genes in a 
Venezuelan equine encephalitis virus replicon particle system is under clinical 
development (Chen et al., 2007). The use of better adjuvants, such as Vaxfectin
®
, has 
been shown to improve DNA vaccines by increasing their immunogenicity and 
protection, highlighting its potential to improve tetravalent dengue DNA vaccines 











Figure 1-10. Antibody dependent enhancement of dengue virus infection. Dengue 
viruses can form immune complexes with heterotypic antibodies from previous 
infection or from maternal transfer. This results in engagement with FcγRs on 
monocytes and eventually increased infection and viral load, increasing severity of 










Figure 1-11. Schematic of the different dengue vaccines currently developed. The 
Sanofi Pasteur vaccine uses a yellow fever virus backbone with prM and E segments 
from the other four DENV serotypes. The NIH vaccine is a chimeric dengue vaccine 
that uses DENV-4 (with 30 nucleotides deleted at the 3’ end of the genome) as the 
backbone. The Inviragen vaccine is a mixture of four recombinant DENV-2 genomes. 
In contrast, the Merck/Hawaii Biotech is a subunit vaccine containing E proteins from 
four DENV serotypes. Another type of vaccine under clinical development is DNA 






1.3.3 Challenges in dengue vaccine development. 
The understanding of protective immune responses against DENV is at present, not 
fully understood (Webster et al., 2009). Since the induction of neutralizing antibodies 
is important for protection against DENV (Kaufman et al., 1987), the plaque-
reduction neutralizing test (PRNT) has been used to test for the presence of these 
protective antibodies against DENV (Russell et al., 1967). However, it is still unclear 
what concentration or type of antibodies constitutes protective immunity. The 
immune mechanisms of protection are also not clearly defined.  
 Besides protection, it is equally important to assess the potential of vaccination 
to cause ADE of dengue infection. This is because although infection with one DENV 
serotype results in lifelong protective immunity against the infecting virus (homotypic 
immunity), secondary infection with a different virus serotype (heterotypic immunity) 
can result in enhanced infection and severe disease outcome (Halstead and O'Rourke, 
1977b, Halstead and O'Rourke, 1977a). For example, the secondary DENV-2 
outbreak in Cuba in 1981 which followed a primary DENV-1 outbreak in 1977 
resulted in severe disease and deaths in both children and older adults, which 
correlated with a large proportion of affected individuals exhibiting a secondary 
serological response (Kouri et al., 1989, Guzman et al., 1990) – a significant contrast 
to the  DENV-1 outbreak observed in 1977, where only mild disease was reported 
even though more than 44% of the population was infected (Halstead 2007). In 
addition, waning levels of transplacentally transferred maternal dengue antibodies in 
infants has been shown to increase the risk of development of DHF/DSS (Kliks et al., 
1988, Chau et al., 2009, Simmons et al., 2007b). Besides non-neutralizing antibodies, 





correlation between enhancing antibody levels and DHF in infants for DENV-3 
infections (Libraty et al., 2009) while DENV-2 predominated in the earlier two 
studies (Kliks et al., 1988, Chau et al., 2009, Simmons et al., 2007b). Hence while 
ADE remains to be proven conclusively as a pathogenic process for severe dengue in 
humans, it cannot be dismissed but should instead be an important consideration in 
vaccine design and development.  Meanwhile, elucidating the mechanisms of ADE of 
DENV infection in pathogenesis should be a priority for research. 
The study of pathogenesis is often aided by animal models, which 
unfortunately is lacking for dengue. Although primates and mouse models may 
display some features of human dengue disease, each have their significant limitations 
(Table 1-1) (Yauch and Shresta, 2008, Rothman, 2011). Common marmosets have 
been shown to be highly sensitive to DENV infection and display clinical signs, 
including thrombocytopenia, leucopenia and fever (Omatsu et al., 2012, Omatsu et al., 
2011). Also, high doses of DENV injected intravenously in Rhesus macaques can 
induce haemorrhagic signs similar to haemorrhagic manifestations observed in 
humans (Onlamoon et al., 2010). However, these primate models can be costly and 
inaccessible to many laboratories. Furthermore, whether similar disease can be re-
capitulated with other clinical isolates remain to be determined. On the other hand, in 
mice, most models rely on mouse-adapted viruses for infection as human clinical 
isolates do not replicate well in these animals (Table 1-1). Many of the mouse models 
also display limited viraemia and signs of disease that are often observed in humans. 
AG129 mice which lack interferon-alpha or interferon-beta (IFNα/β) and IFNγ 
receptors may show some dengue-like characteristics such as intestinal haemorrhage 
and vascular leakage, but have limited usefulness for investigation into the immune 





immunocompromised. Humanized mouse technology may address some of these 
limitations (Bente et al., 2005, Jaiswal et al., 2009) although current models still fall 








Table 1-1. Mouse models of dengue infection. The different mouse-adapted strains 
and their respective limitations in the study of dengue pathogenesis.  Table adapted 








1.4 Immune responses and their consequences to dengue infection. 
1.4.1 Antibody responses in protection and pathogenesis.  
In non-immune individuals, immunoglobulin M (IgM) antibodies are first generated 
after DENV infection, which peaks at ~2 weeks following fever onset that then 
decline to undetectable levels over the next 2-3 months (Guzman et al., 2010). 
Immunoglobulin G (IgG) antibodies are generated only at the end of the first week of 
illness (Figure 1-12). Most of these react against the NS1, E and prM proteins (de 
Alwis et al., 2011). While anti-prM antibodies may result in enhancement of DENV 
infection (Dejnirattisai et al., 2010), antibodies targeted against the E proteins are 
protective and are produced at levels sufficient to neutralize all DENV serotypes 
during early convalescence following acute infection (Zompi et al., 2012, Sabin, 
1952b). However, as antibody levels decline, only serotype-specific antibodies retain 
the ability to neutralize and protect the host from re-infection. Moreover, non-
neutralizing and cross-reactive or sub-neutralizing levels of antibodies may result in 
more severe disease outcome (Simmons et al., 2007a, Halstead and O'Rourke, 1977b, 
Halstead, 1988, Kliks et al., 1988, Halstead et al., 1980). These observations support 









Figure 1-12. Viraemia and antibody responses in primary dengue infection. After 
dengue infection, NS-1 can be first detected. As viraemia subsides, IgM antibodies 
are first produced followed by IgG antibodies produced at the later stage post-






Protective antibody responses. 
DENV neutralization is a “multiple-hit” phenomenon, which occurs when virions are 
bound by antibodies with stoichiometry exceeding a required threshold (Figure 11). 
Both antibody affinity and epitope accessibility are important determinants for virus 
neutralization (Pierson and Diamond, 2008, Pierson et al., 2007, Pierson et al., 2008). 
Antibody affinity is defined by the fraction of epitopes bound by antibodies at non-
saturating concentrations and has been found to correlate with neutralizing activity in 
vitro (Figure 1-13A). For example, the recognition of neutralizing epitopes can vary 
with different viral strains, affecting neutralizing properties of antibodies targeting the 
particular epitope (Sukupolvi-Petty et al., 2010, Wahala et al., 2010). Epitope 
accessibility, on the other hand is defined by the number of epitopes on the virions 
accessible for binding and is affected by steric constraints from virion structure, 
structural dynamics of virus, differences in oligomeric states during virion maturation 
and antibody size (Dowd and Pierson, 2011). A reduction of epitope accessibility 
would indicate that an increased fraction of epitope occupancy will be required for 
virus neutralization (Figure 1-13B). Overall, these studies suggest that potent 
antibodies can neutralize DENV by binding to a small fraction of available epitopes 
whereas weakly neutralizing antibodies require high occupancy for DENV 
neutralization. 
Studies from mouse monoclonal antibodies have demonstrated that the most 
potent neutralizing antibodies are generally serotype-specific and binds to EDIII while 
the cross-reactive, weakly neutralizing antibodies typically binds to EDI/EDII 
(Sukupolvi-Petty et al., 2007a). However, this contrasts with the observation that most 
of the neutralizing human antibodies elicited after DENV infection are targeted 





2012, Wahala et al., 2009, Beltramello et al., 2010, Lai et al., 2008). To explain for 
the differences observed, recent studies by de Alwis et al proposed that many of these 
strongly neutralizing antibodies recognize the quaternary structure epitope, expressed 
only when E proteins are assembled on the virion but not to the ectodomain of 
purified soluble E proteins. In another study, Williams et al. revealed that the initial 
production of cross-reactive antibodies is above threshold levels, resulting in 
protection (Williams et al., 2012). This protection provided by these antibodies are, 








Figure 1-13. Antibody affinity and epitope accessibility are important 
determinants for virus neutralization. Neutralization of viruses requires 
stoichiometry that exceeds a threshold (estimated to be ~ 30 antibodies). Below the 
threshold, antibody dependent enhancement results. (A) Antibody affinity is defined 
as the fraction of epitopes bound by antibody at non-saturating concentrations. For 
example, in a virus exposing 180 E protein epitopes, an average of 90 antibody 
molecules are occupied at antibody concentration = Kd. (B) Epitope accessibility 
governs occupancy requirements for neutralization. A reduction of epitope 
accessibility requires increased fraction of epitopes to be occupied for virus 








Antibody responses in dengue pathogenesis  
When DENV is opsonised with antibodies at levels below the neutralization threshold, 
these antibodies are unable to inhibit virus fusion, resulting in ADE of DENV 
infection in FcγR-bearing cells (Halstead and O'Rourke, 1977a). Furthermore, in 
patients with secondary infection, the rates of prM antibody responses are 
significantly higher than those with primary infection (Lai et al., 2008). These 
antibodies can bind to immature viruses, which are abundantly present due to 
inefficient cleavage of the prM protein (Rodenhuis-Zybert et al., 2011, Junjhon et al., 
2010), facilitating efficient binding and cell entry into FcγR-bearing cells. The 
increased uptake of these virions can then be processed by furin in the cell to form 
highly infectious virions, resulting in enhanced infection (Dejnirattisai et al., 2010, da 
Silva Voorham et al., 2012, Rodenhuis-Zybert et al., 2010). 
As indicated earlier, it has been challenging to test the ADE hypothesis in 
animal models because DENV replicates poorly in animals and symptoms of dengue 
disease are hard to reproduce in animal models. Nonetheless, using AG129 mice, 
passive administration of sub-neutralizing doses of antibodies was observed to 
enhance DENV infection and disease severity, with symptoms resembling severe 
dengue disease in humans (Zellweger et al., 2010, Balsitis et al., 2010, Paradkar et al., 
2011). Similarly, passive administration of cross-reactive antibodies in primates 
showed enhanced viraemia, although attempts to reproduce DHF in primates have 
been unsuccessful (Halstead and O'Rourke, 1977a, Goncalvez et al., 2007). Future 
studies using better animal models will provide more important insights to dengue 






1.4.2 T-cell responses in protection and pathogenesis 
Protective T-cell responses  
Cellular immune responses have been proposed to play an important role in virus 
clearance. During dengue infection, viral peptides presented on surface of infected 
cells by major histocompatibility complex (MHC) molecules can be recognized by T-
cells, resulting in cell lysis and release of antiviral cytokines which can restrict viral 




 T-cells in protection has been shown in mice 
(Yauch et al., 2009, Yauch et al., 2010). However, in humans, the protective role of 
T-cells is more difficult to define as the humoral response also contributes to 
protection. Nevertheless, it is possible to test for correlations between T-cell 
responses and disease outcome. For example, Hatch et al., demonstrated that higher 
frequencies of DENV-specific TNFα, IFNγ and interleukin-2 (IL-2) producing T-cells 
correlated with subclinical infection as compared to those who developed 
symptomatic secondary infection (Hatch et al., 2011). The protective effect of T-cells 
can also be inferred from human-leukocyte antigen (HLA) association studies with 
dengue disease, as specific HLA alleles were significantly more common among 
individuals with DF than those with DHF/DSS (Stephens, 2010). 
 
T-cell responses in dengue pathogenesis  
It is proposed that during secondary infection, the preferential expansion of lower 
avidity cross-reactive memory T-cells resulting from the previous infection may out-
compete the higher avidity specific naïve T-cells, delaying viral clearance and 
resulting in production of these pro-inflammatory cytokines (e.g. IFNγ, TNFα, IL-13) 
which can affect vascular permeability (Rothman, 2011). The model, also described 





during primary dengue infection in infants as only immunoglobulins but not T cells 
can cross the placenta from maternal to foetal blood. The lack of good animal models 
has hampered the full understanding of the role memory T-cells in disease 
pathogenesis. However, more insights on T-cell immunity can be derived on 
prospective cohort studies and clinical trials. For example, Mongkolsapaya et al. 
demonstrated that T-cells in severe infection have a low affinity for the current 
infecting serotype but high affinity for the previous infection (Mongkolsapaya et al., 
2003). Furthermore, functional studies indicated that severe dengue patients have T-
cells that express high levels of IFNγ and TNFα but low levels of CD107a, a marker 
for cytotoxic degranulation as compared to patients with uncomplicated dengue 
infections (Duangchinda et al., 2010). It remains to be shown, however, if T-cells can 
directly contribute to capillary leakage in vivo. Future prospective cohort studies or 
vaccine trials will continue to provide more significant insights on the role T-cell 






1.4.3 Cytokine responses involved in pathogenesis 
Studies have shown that the plasma levels of pro-inflammatory and vasoactive 
cytokines are up-regulated in patients with DHF/DSS and disease severity is 
correlated with the degree of elevation (Table 1-2). The induction of cross-reactive T-
cells during secondary infection is thought to trigger a “storm” of cytokines and other 
pro-inflammatory molecules, resulting in increased vascular permeability and plasma 
leakage. Other than T-cells, studies have also indicated the release of many of these 
cytokines in DENV infected endothelial cells (Dalrymple and Mackow, 2012), 
dendritic cells (Rodriguez-Madoz et al., 2010) and monocytic cells (Espina et al., 
2003).  
 Human studies have identified cytokines which correlate with disease severity 
although whether these correlates play a mechanistic role, or are just bystander 
statistical associations, remains to be answered largely due to the lack of a good 
animal model for dengue. An alternative approach could be to identify regulators of 
cytokine expression during DENV infection. One of the central regulators is C-type 
lectin domain family 5, member A (CLEC5A) expressed in monocytes and 
macrophages. It has been demonstrated that the interaction of DENV and CLEC5A in 
monocytes and macrophages results in up-regulation of TNFα, IL-6, IL-8, 
macrophage inflammatory protein (MIP)-1α and interferon-inducible protein (IP)-10, 
resulting in increased haemorrhage and vascular permeability in signal transducer and 
activator of transcription (STAT)-deficient mice (Chen et al., 2008, Cheung et al., 
2011). The other is the macrophage inhibitory factor (MIF), which has been shown to 
be important in the pathogenesis of DENV infection as pro-inflammatory cytokines 
such as TNFα, IL-6 and prostaglandin E2 was reduced in MIF-/- mice (Assuncao-





in up-regulation of these cytokines and increased plasma leakage in mice (Chuang et 
al., 2011). Lastly, FcγR cross-linking in monocytes by DENV immune complexes can 
trigger secretion of pro-inflammatory cytokines such TNFα, IL-1β, IL-6, and IL-8 and 
anti-inflammatory cytokines IL-10 and TGFβ in monocytes (Gerber and Mosser, 
2001), some of which are associated with plasma leakage and severe disease outcome.  
Amongst the up-regulated cytokines in severe dengue cases, TNFα is of 
particular interest because of its ability to increase endothelial permeability (Anderson 
et al., 1997). Notably, TNFα308A allele, which leads to overproduction of this 
cytokine, is associated with DHF (Perez et al., 2010, Fernandez-Mestre et al., 2004). 
Another cytokine, IL-10 can result in reduced levels of nitric oxide and hence 
increased levels of pro-inflammatory cytokines. IL-10 has also been shown to 
correlate with platelet decay and reduced function, resulting in enhanced disease 
severity (Libraty et al., 2002a). On the other hand, IL-6 can elevate levels of tissue 
plasminogen activator which is important in the control of fibrinolysis (Duchini et al., 
1996) and IFNγ has been shown to up-regulate FcγRI expression in monocytes (Schiff 
et al., 1997). Different effects from produced by different cytokines suggests that it is 
likely that multiple cytokines and soluble factors contribute simultaneously in a 
complex way to result in DHF/DSS. 
The literature on the critical factors that lead to DHF/DSS indicates that this 
subject is far from being fully understood.  However, it is likely that pathogenesis of 
DHF hinges on successful replication of DENV in humans that then trigger a cascade 
of immunological events that lead to compromised vascular integrity.  Understanding 









Table 1-2. Cytokines, soluble factors and coagulation factors up-regulated in 
DHF/DSS patients. Pro-inflammatory cytokines are up-regulated in patients with 
severe dengue infection, some of which have been shown to be important in severe 







1.5 Molecular processes in DENV infection  
1.5.1 Dengue life cycle 
The early events of DENV infection in humans are still poorly understood. It is 
thought that after a mosquito bite, the infected immature Langerhan’s cells in the 
dermis migrate to the lymph nodes, resulting in infection of monocytes and 
macrophages, the primary targets of dengue infection and dissemination (Kou et al., 
2008). The identification of many different possible receptors in these cells reflects a 
lack of consensus on the cellular receptor for DENV, some of which include heparan 
sulfate (Chen et al., 1997), heat-shock protein 90 (Reyes-Del Valle et al., 2005), 
CD14 (Chen et al., 1999) and C-type lectins CLEC5A (Chen et al., 2008), dendritic 
cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) 
(Tassaneetrithep et al., 2003) and mannose receptor (Miller et al., 2008). After 
receptor engagement, DENV particles appear to move along the cell surface and enter 
the cell by clathrin-mediated endocytosis (van der Schaar et al., 2008, Halstead et al., 
1980). Besides direct interaction with a cellular receptor, DENV has an alternative 
entry pathway into monocytes/macrophages. In the presence of dengue-specific 
antibodies, immune complexes formed can interact with FcγR present on myeloid 
cells, resulting in increased entry and infection via FcγR-mediated phagocytosis (van 
der Schaar et al., 2009, Halstead et al., 1980). Once internalized, the acidic 
environment in the endosomes triggers trimerization of the E protein, resulting in 
fusion of viral and cell endosomal membranes (Kuhn et al., 2002, Li et al., 2008). The 
released RNA is then translated by the host ribosomes. Subsequently, the polyprotein 
is cleaved by cellular and viral proteases at specific sites. Using the negative-sense 





with the capsid protein and packaged into virions. Immature virions are first formed in 
the endoplasmic reticulum, with prM acting as a scaffold to prevent premature virus 
fusion. Subsequently, the prM is cleaved into pr and M by a cellular protease (furin) 
in the trans-Golgi network (Yu et al., 2008). Mature infectious particles formed are 








Figure 1-14. Life cycle of dengue virus. Following receptor binding to dengue virus, 
the virus enters the cell via clathrin-mediated endocytosis. The acidic pH in the 
endosomal compartments results in conformational change of the virus and viral 
fusion. RNA released into the cytoplasm is then replicated and translated. Immature 
virions formed in the endoplasmic reticulum transits to the Golgi where it is cleaved 
by furin. Matured particles formed are then released out of the cell by exocytosis. 






1.5.2 Subversion of innate immunity to establish infection in monocytes 
The first line of the host’s defence against DENV is the production of 
interferons (IFN), which has been demonstrated to inhibit DENV infection (Diamond 
et al., 2000, Johnson and Roehrig, 1999). DENV can interact with pattern recognition 
receptors (PRR), including toll-like receptors (TLR) e.g. TLR3, TLR7 and TLR8 
(Tsai et al., 2009), RNA helicases e.g. retinoic acid-inducible gene (RIG-I), 
Melanoma Differentiation-Associated protein 5 (MDA5) (Nasirudeen et al., 2011) 
and C-type lectins DC-SIGN and CLEC5A to induce up-regulation of pro-
inflammatory cytokines and IFN (Faure and Rabourdin-Combe, 2011). The binding of 
secreted type I IFN to IFN receptors then activates the Janus kinase (Jak)/STAT 
signaling pathway to stimulate production of interferon stimulated genes (ISG) 
(Darnell et al., 1994), which include the interferon-induced transmembrane (IFITM) 
proteins, viperin, ISG20 and double-stranded RNA activated protein kinase (PKR). 
All of these ISGs have been shown to restrict dengue infection by either preventing 
entry or replication (Chan et al., 2012, Jiang et al., 2010).  
To overcome the antiviral effects of IFN for successful infection, several 
studies have shown that the non-structural genes of DENV (NS2A, NS4A, NS4B and 
NS5) can block IFN signaling by reducing STAT-1 activation (Grant et al., 2011, 
Munoz-Jordan et al., 2003). Notably, different strains of DENV have been shown to 
suppress type I IFN response at different rates (Umareddy et al., 2008), although type 
I IFN serum levels were not necessarily associated with strains that result in severe 
disease outcome (Takhampunya et al., 2009). Dengue NS5 has also been shown to 
bind and reduce STAT-2 abundance via ubiquitination and proteasome activity 





different strategies to subvert antiviral response for successful replication (Pagni and 








Figure 1-15. DENV can subvert the interferon response in infected cells. DENV 
can be recognized by TLR3 and RIG-I/MDA5 to signal via signalling molecules, 
activating IRF3 to activate transcription of IFN. IFN produced can bind to IFN 
receptors, resulting in activation of Jak/STAT pathway. The phosphorylated STAT-1 
and STAT-2 can then form a transcription factor complex with interferon-regulatory 
factor-9 (IRF9) to result in induction of ISG and antiviral responses. Dengue NS 
proteins have been shown to interfere at different parts of the pathway to allow virus 






1.6 Molecular insights in neutralization and enhancement of DENV infection 
DENV infection can be either neutralized or enhanced in the presence of DENV 
specific antibodies. However, the mechanisms underlying neutralization and 
enhancement of DENV infection in monocytes are still not fully understood even 
though it represents an important piece of the puzzle of how dengue pathogenesis and 
immunity interact. Previous studies have examined neutralization of DENV using 
kidney cell lines such as LLC-MK2, Vero and BHK-1 cells. However, these cells do 
not express FcγR naturally and are not the primary targets of DENV infections. 
Monocytes, on the other hand, play a central role in DENV replication and bear FcγR 
important for neutralization or enhancement of DENV infection.  
 
1.6.1 The role of FcγR in DENV neutralization 
The stoichiometric requirement for neutralization can be influenced by different cell 
types, possibly due to the use of different receptors for DENV infection. This can be 
illustrated by the differences in neutralization titers when Vero cells or DC-SIGN 
transfected Raji cells were used (Putnak et al., 2008). Entry through FcγR in 
monocytes could hence potentially influence the stoichiometric requirement for 
DENV neutralization. 
FcγR are expressed by immune cells, including dendritic cells, natural killer 
cells, monocytes, macrophages, neutrophils and mast cells, and contribute to the 
protective functions of the immune system (Joller et al., 2011). These receptors can be 
broadly classified into two main classes: (i) activating receptors (FcγRIA, FcγRIIA, 
FcγRIIIA) which phosphorylate the immunoreceptor tyrosine activating motif (ITAM) 
to activate kinases and downstream signaling cascades and (ii) inhibitory receptors 





triggers dephosphorylation of downstream signaling molecules (Huang et al., 2003) 
(Figure 1-16). Unlike FcγRIA which is a high affinity receptor for both monomeric 
IgG and immune complexes and signals through a dimer of γ-subunits which contains 
the ITAM motif, FcγRIIA and FcγRIIIA only binds to immune complexes but not 
monomeric IgG, and signals through ITAM motif present within the receptor itself 
(Woof and Burton, 2004, Aderem and Underhill, 1999). After engagement of 
activatory FcγR by immune complexes, proto-oncogene tyrosine-protein kinase (Src) 
and spleen tyrosine kinase (Syk) family kinases are recruited and activated to initiate 
an activating signaling cascade which results in phagocytosis of immune complexes 
(Strzelecka et al., 1997). On the contrary, inhibitory FcγR counteracts this signaling 
by recruitment and activation of phosphatidylinositol 3,4,5-trisphosphate 5 
phosphatases (SHIP) and Src homology phosphatases (SHP). The ratio of the local 
concentrations of activating to inhibitory FcγR recruited during phagocytosis hence 
determines if the immune complexes are taken up or not (Syam et al., 2010).  
Although activating FcγRs signal through ITAM motifs to mediate uptake, 
engagement of different FcγRs can result in disparate signaling and trafficking 
pathways. For example, activation of FcγRI activates phospholipase-D1 and 
sphingosine kinase-1 to induce proinflammatory cytokines and trafficking to late 
endosomes/lysosomes for antigen presentation whereas activation of FcγRIIA 
activates phospholipase C-gamma-1 to increase intracellular calcium, differential 
trafficking which results in impaired antigen presentation and proinflammatory 
cytokine expression (Dai et al., 2009). Therefore, besides presence or absence of 
FcγRs, the type of FcγRs present will likely influence the stoichiometric requirement 
for DENV neutralization. Indeed, using COS-7 transfectants, Rodrigo et al. 





neutralize DENV as compared to untransfected cells. This is in contrast to FcγRIIA 
which required more antibodies to neutralize the virus than untransfected cells 
(Rodrigo et al., 2009), suggesting that the preferential engagement of FcγRI is likely 
to be important in virus neutralization. Studies by Moi et al. support these 
observations by demonstrating that FcγRIIA transfectants of baby hamster kidney 
cells (BHK-21) required higher neutralizing antibody titers than untransfected cells 
(Moi et al., 2010). On the other hand, the presence of FcγRIIB in monocytes can 
interact with immune complexes, resulting in inhibition of FcγR-mediated 
phagocytosis (Siedlar et al., 2011, Tridandapani et al., 2002). This may prevent 
DENV entry and hence also result in neutralization. At present, the role of FcγRIIB in 
DENV neutralization is unknown.  
There are at least two mechanisms in which antibodies can neutralize DENV 
in cells. From studies performed on kidney cell lines, it has been shown that 
antibodies neutralize flaviviruses by either blocking attachment to cellular receptors 
(Crill and Roehrig, 2001) or blocking viral fusion intracellularly (Gollins and 
Porterfield, 1986). The most potent antibodies are thought to neutralize virus infection 
by inhibiting viral fusion. For example, Thompson et al. showed that antibody E16, 
which is a potent antibody that binds to EDIII of WNV, is capable of inhibiting at the 
post-attachment step in Vero cells (Thompson et al., 2009). However, whether the 
antibody blocks attachment or fusion, the immune complexes would be cleared from 
the circulation by FcR-expressing cells, suggesting that only antibodies that are 
capable of blocking fusion can neutralize DENV after FcR-mediated uptake. In other 
words, the threshold for DENV neutralization FcR-bearing cells is likely to be 
determined by the antibody concentration that inhibits virus fusion in the cell. 





neutralization and enhancement of dengue infection, indicating that the utilization of 
different FcRs by different antibodies may also affect the stoichiometric requirement 
for virus neutralization. Despite the importance of FcRs in mediating DENV 
neutralization, a clear understanding of the molecular basis and events involved in 
DENV neutralization, especially in the context of FcR-bearing monocytes, is still 
elusive.  Understanding DENV neutralization in FcR-bearing monocytes is thus one 








Figure 1-16. Properties of different FcγR. Activatory receptors FcγRI, FcγRIIA and 
FcγRIIIA are present on monocytes and macrophages but have differing IgG binding 
affinity. Also, FcγRI and FcγRIIIA require the common γ-chain for signaling whereas 
ITAM in FcγRIIA is within the receptor chain. FcγRIIB, on the other hand, contains 
the ITIM motif to counteract signaling from activating FcγRs. Figure adapted from 






1.6.2 The role of FcγR in ADE of dengue infection  
Besides the clearance of DENV that has been neutralized by antibodies, the 
interaction of immunoglobulin and FcγRs is also important for ADE of DENV 
infection. In animal models, it has been demonstrated that administration of antibody 
variants with reduced FcγR binding displayed therapeutic efficacy (Balsitis et al., 
2010). Blocking FcγRs in PBMCs with monoclonal antibodies also significantly 
reduced ADE of dengue infection (Boonnak et al., 2011, Kou et al., 2008). 
Furthermore, the binding affinity of the FcγRs to IgG can determine the outcome of 
infection. For example, different antibody isotypes can enhance DENV replication 
differently. IgG1 and IgG3 bind FcγRs with high affinity and hence result in greater 
levels of infection as compared to IgG4 which bind with reduced affinity (Rodrigo et 
al., 2009). Additional evidence comes from case-control studies, which revealed that 
the polymorphic variant at position 131 of FcγRIIA, which correlated with reduced 
binding and uptake of immune complexes was associated with reduced risk for DHF 
(Garcia et al., 2010, Loke et al., 2002). Among the FcγRs, FcγRIA and FcγRIIA have 
been shown to be important in ADE of DENV infection as blocking either of these 
receptors resulted in significant reduction in DENV replication (Kou et al., 2008, 
Boonnak et al., 2011). Furthermore, mutagenesis in the ITAM tyrosine residues of 
either receptor can result in reduced infectivity (Rodrigo et al., 2006). Collectively, 
these studies suggest that the interaction between antibodies and FcγRs is important 
for ADE of dengue infection to occur.  
1.6.3 Does ADE of DENV infection suppress innate immune responses? 
Although engagement of activating FcγRs is important for FcγR-mediated uptake of 





induce ISG expression when the inhibitory FcγRIIB is not co-ligated (Dhodapkar et 
al., 2007). The induction of ISGs from this signaling pathway is independent of IFN 
signaling and is proposed to signal via activation of Syk and STAT-1 after 
engagement of activating FcγRs (Dhodapkar et al., 2007). ADE of DENV infection 
would therefore not be possible if FcγRIIB is not co-ligated, as the engagement of 
activating FcγRs would have led to induction of ISG and suppressed viral replication. 
Despite FcγRIIB being a likely candidate, the role of FcγRIIB in ADE of dengue 
infection is still not known. Even if FcγRIIB is not involved, other immune inhibitory 
receptors may play a role in ADE and these have not been systematically examined in 
DENV infection. Further studies are thus needed to identify molecular pathways 
involved in ADE of DENV infection and provide new perspectives for rational design 
of therapeutic strategies against severe disease outcome.  
It has also been suggested that ADE results in a shift to a TH2-type cytokine 
response. This response is associated with the up-regulation of IL-10 and suppressor 
of cytokine signaling (SOCS) molecules to suppress IL-12, IFNγ production and the 
Jak/STAT signaling pathway (Chareonsirisuthigul et al., 2007). This phenomenon, 
also described as “intrinsic ADE” by Halstead and colleagues, is hypothesized to 
create an environment favorable for increased viral replication and infection (Figure 
1-17). Recently, it has also been shown by Modhiran et al., that the TLR responses 
triggered by DENV can be suppressed by activation of sterile alpha-and armadillo-
motif-containing protein (SARM) and TRAF family member-associated NFκB 
activator (TANK) (Modhiran et al., 2010), resulting in suppressed IFN responses. 
However, Kou et al. demonstrated that increased virus production in primary human 
monocytes was not associated with reduced secretion of type I IFN or increased 





promoter polymorphisms which resulted in differential expression of IL-10 were not 
found to affect DENV replication under ADE conditions (Boonnak et al., 2011). 
These evidences indicate the presence of other unknown host mediators involved in 
the suppression of innate responses triggered during by either FcγR or PRR during 
ADE of DENV infection, one of which could be FcγRIIB.   






Figure 1-17. Intrinsic antibody-dependent enhancement in monocytes. DENV can 
interact with pattern recognition receptors (PRR) to up-regulate type I interferons to 
limit viral replication. In contrast, DENV immune complexes can interact with FcγR 
to upregulate IL-10 and SOCs to inhibit type I interferons and permit viral replication. 






1.7 Gaps in knowledge in DENV neutralization and ADE. 
The literature review thus indicates that a better understanding of neutralization and 
ADE of dengue infection at the molecular level is required. Defining the determinants 
for virus neutralization could lead to the design of an effective vaccine that can 
protect against all four DENV serotypes while minimizing the risk of ADE of DENV 
infection. Previous investigations have made use of kidney cell lines, such as LLC-
MK2, Vero, and BHK-1 cells (Roehrig et al., 2008). However, these cells neither 
express FcγR naturally nor are primary targets of dengue virus in human infections. 
Monocytes, on the other hand, play a central role in DENV replication (Kou et al., 
2008) as well as in the removal of the immune complexes in vivo (Sun et al., 2008, 
Huber et al., 2001, Van Strijp et al., 1990). Although activating FcγRs have been 
shown to be important in ADE of dengue infection, the exact role of activating and 
inhibitory FcγR in virus neutralization have yet to be investigated. To address this, the 
events of interaction between DENV immune complexes and monocytic cells will 
have to be examined in greater detail. 
In addition, cross-linking of activating FcγRs has been shown to signal an 
early antiviral response by inducing the type-I interferon-stimulated genes (ISGs), 
unless the inhibitory FcγRIIB is co-ligated (Dhodapkar et al., 2007). Entry through 
the Fc-receptor pathway would thus place DENV in an intracellular environment 
unfavorable for enhanced replication. Therefore, for ADE to occur, engagement of 
FcγRIIB or other similar inhibitory receptors could be an important event in 
mediating ADE of dengue infection. This interaction, however, has not been reported. 
Hence, the mechanism of how antiviral immune responses are suppressed in 





The specific aims of this thesis are thus: 
1. Explore the early interactions involved in antibody-mediated neutralization 
of DENV in monocytes. 
2. Determine the different FcγR usage during antibody-mediated 
neutralization and enhancement of DENV in monocytes. 
3. Elucidate the FcγR signalling events in ADE of DENV infection of 
monocytes. 
1.7.1 Brief description of approaches employed 
To investigate the early intracellular events of dengue immune complexes in 
monocytic cells, fluorescent labelled DENV was used. Neutralized dengue immune 
complexes, when in complex with homotypic or heterotypic antibodies, were added to 
THP-1 cells and visualized under confocal immunofluorescence. Moreover, knock-
down and over-expression studies were used to identify key receptors involved in 
uptake of antibody-opsonized DENV and neutralization. As previous reports have 
indicated that only a small subset of monocytes are infected even under ADE 
conditions (Kou et al., 2008; Boonnak et al., 2011), sub-cloning of THP-1 cells was 
performed to obtain subclones that exhibited increased uptake of these immune 
complexes. Thereafter, these clones were used to investigate the co-factors and 
signaling pathways important in mediating either resistance or susceptibility to ADE 






















2.1 Cells.   
BHK-21, C6/36, THP-1, K562 and Vero cells were purchased from American Type 
Culture Collection (ATCC) and cultured according to ATCC recommendation.  
Primary monocyte harvesting and culture was done in collaboration with 
Summer Zhang and approved by the National University of Singapore Institutional 
Review Board (NUS IRB reference code 12-160). Venous blood from the principal 
investigator was collected in BD sodium heparin vacutainers (Biomed Diagnostics, 
Singapore). The blood was then diluted with 2 volumes of 0.5% bovine serum 
albumin (BSA, Sigma Aldrich, Singapore) in phosphate buffered solution (PBS, 1
st
 
Base, Singapore) (0.5% PBS/BSA), and carefully layered onto Ficoll-hypaque (GE 
healthcare, Singapore). The blood was then subjected to centrifugation at 750 x g, 
without brakes. The interphase cells containing the peripheral blood mononuclear 
cells (PBMC) were aspirated and transferred to a clean tube. PBMC were washed 3 
times with 0.5% PBS/BSA and resuspended in growth medium (RPMI-1640 
supplemented with 10% fetal bovine serum, 100U/ml penicillin and 100µg/ml 
streptomycin). The cells were then counted and seeded into T25 tissue culture flasks 
(NUNC, Bio Laboratories, Singapore) at 1x10
7
 per flask. The cells were incubated at 
37°C, 5% CO2 for 2.5hrs to allow the monocytes to adhere to the flask surface. The 
adhered cells were washed 5 times with PBS to remove the non-adherent lymphocytes, 
and replenished with fresh growth medium. These monocytes were allowed to recover 






2.2 THP-1 subclones 
To obtain subclones of THP-1, the THP-1 cell line was diluted to 0.5 cell/well by 
limiting dilution in 96-well plates. The subclones were grown in growth media and 
monitored over several weeks. With sufficient cell density, the cells were transferred 
to 24 well plates, 6 well plates and subsequently T-25 flasks. At low passages, the 
cells were stored by cryopreservation. The rates of uptake of DiD-labeled DENV 
during ADE of dengue infection were assessed for ~50 subclones as described below 
in section 2.12. Of these subclones, we selected THP-1.2R and THP-1.2S as their 
rates of uptake was higher than the parental THP-1.  
 
2.3 Antibodies.   
3H5 and 4G2 chimeric human/mouse IgG1 and IgG4 antibodies were constructed as 
previously described (Hanson et al., 2006).  Briefly, mRNA was prepared from 
hybridoma cells and total cDNA was used as a template to amplify the variable heavy 
and light chain. Variable region specific primers were used to amplify both the heavy 
and light chain variable regions with addition of recognition sites to allow cloning 
into the human IgG1 constant region expression vector. Constructs encoding chimeric 
IgG1 were transfected into 293-F cells by use of 293 fectin (Invitrogen). Proteins 
were purified using protein A sepharose beads (Amersham) and purity of IgG was 
confirmed using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) analyses. 
For staining and visualization, primary and secondary antibodies were 






Table 2-1. Antibodies used in this thesis and the companies from which they 
were purchased from  
 
Primary antibodies Company 
LAMP-1 BD Biosciences 
FcγRI eBioscience 
FcγRIIA Stem cell biology 
FcγRIIB Abcam 
Syk  (4D10) Abcam 
SHP-1 Abcam 
  p-SHP-1 Abcam 
pSTAT-1 eBiosciences 
STAT-1 eBiosciences 
Anti-phosphotyrosine antibody (4G10) Millipore 
IFNαR Abcam 
GAPDH Abcam 






Cy3 conjugated anti-human antibody Santa Cruz 
Alexa488 conjugated anti-mouse antibody Invitrogen 





2.4 Human sera. 
Human sera used in this study were obtained from the early dengue infection 
and control (EDEN) study as previously described (Low et al., 2006), approved by the 
National Healthcare Group (NHG) Institutional Review Board (DSRB B/05/013).  
Upon consent, full history was taken and patients were categorized into DENV-
positive or DENV-negative groups based on reverse transcription polymerase chain 
reaction (RT-PCR). Patients with sera obtained within the first 72 hours from illness 
onset and negative in anti-dengue IgM and IgG enzyme-linked immunosorbent assay 
(ELISA) were assigned as primary infection. Sera obtained from the patients 3-4 
weeks post illness-onset were assigned as convalescent sera and used in this study.  
 
2.5 Viruses. 
DENV-1 (07K3640DK1) and DENV-3 (05K863DK1) are clinical isolates obtained 
from the EDEN study (Low et al., 2006). DENV-2 (ST) is a clinical isolate from the 
Singapore General Hospital and DENV-4 (H241) was obtained from ATCC. Viruses 
were propagated in the Vero cell line and harvested 96 hours (hr) post infection and 
purified through 30% sucrose.  Virus pellets resuspended in 5 mM HEPES, 150 mM 
NaCl, 0.1 mM EDTA, pH 7.4 (HNE) buffer were stored at -80˚C until use. Infectious 
titer was determined by plaque assay.  
Virus-like particles (VLP) were obtained as previously described and 
produced in collaboration with Eugenia Ong (Purdy and Chang, 2005). Briefly, VLP 
consisting of DENV-2 prM and E proteins secreted from transformed COS-1 cells 
were concentrated and partially purified from clarified tissue culture medium by 
ultracentrifugation at 20,000 rpm for 3 hours at 4°C. The pellet was resuspended in 





2.6 Affinity measurements by indirect ELISA. 
Microtiter plates were coated with purified DENV-2 ST (~2 x 10
6
 pfu/ml) in 
carbonate buffer, pH 9.6. Wells were washed twice with phosphate-buffered saline 
(PBS), blocked for 90min at room temperature (25˚C) with 5% skim milk and 
subsequently washed twice with PBS-T (PBS containing 0.05% Tween-20). Serial 2-
fold dilutions of monoclonal antibodies (mAb) were added to the plates. This range of 
concentrations was determined to cover the full range of binding, from undetectable 
binding to saturation. Antibodies were allowed to bind for 90min at room 
temperature. Subsequently, the microtiter plates were washed twice with PBS-T 
followed by addition of 1/1000 dilution of either horseradish peroxidase (HRP) 
conjugated goat anti-mouse immunoglobulins or 1/1000 dilution of HRP conjugated 
goat anti-human immunoglobulins and incubated for 90min at room temperature. 
Following this incubation, microtiter plates were washed twice with PBS-T and once 
with PBS. Antibody binding was visualized by addition of 100μl of 3,3’,5,5’-
tetramethylbenzidene substrate (TMB) (Sigma) and incubation of 10min at room 
temperature, followed by addition of 160μl of 2M sulphuric acid. The absorbance was 
read at 450nm using plate reader (Biorad). 
 
2.7 Plaque assay.  
Serial dilutions (10-fold) of virus were added to BHK-21 cells in 24 well plates and 
incubated for 1hr at 37
o
C. Media was aspirated and replaced with 0.8% methyl-
cellulose in maintenance medium (RPMI-1640, 2% FCS, 25mM HEPES, penicillin 
and streptomycin). After 5 days at 37˚C, cells were fixed with 20% formaldehyde at 
RT for 20min, washed with water, and 1ml of 1% crystal violet was added for 20min. 





2.8 Plaque reduction neutralization test (PRNT).   
PRNT was carried out on BHK-21 cells as previously described with some 
modification (Russell et al., 1967). Briefly, a series of 2-fold dilutions of the sera was 
incubated with 40pfu of DENV at 37ºC for 1 hour before adding to BHK-21. The 
highest dilution that neutralized 50% of the plaque forming units is the PRNT50 titer. 
 
2.9 Virus infection in THP-1.  
Serial two-fold dilutions of h3H5 or human sera were incubated for 1hr at 37˚C before 
adding to THP-1 (moi 10). Following 72hrs post-infection, the culture was clarified 
by centrifugation and the infectious titer of dengue virus in the culture supernatant 
quantified with plaque assay. The antibody dilution required to mediate full virus 
neutralization or peak enhancement titers were then determined. 
 
2.10 Quantitative real-time PCR 
Cells were washed thrice in PBS, followed by RNA extraction using RNAeasy kit 
(Qiagen), cDNA synthesis (Biorad) and quantitative real-time PCR (qPCR) (Roche) 
according to manufacturer’s protocol. DENV primers used were targeted at 3’ UTR 
region as described previously (Lai et al., 2007): 
DEN-F(5’-TTGAGTAAACYRTGCTGCCTGTAGCTC);                                                                                                                         
DEN-R(5’-GAGACAGCAGGATCTCTGGTCTYTC).                                                                        
Primers used for ISGs and GAPDH were obtained from Origene, all expressed as 






2.11 Fluorescent labelling of virus.  
The method for 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindodicarbocyanine,4-
chlorobenzenesulfonate salt (DiD)-labelling (van der Schaar et al., 2007b) and 
Alexa594 labelling of DENV is as previously described (Zhang et al., 2010). For DiD 
labeling, ~2.8x10
8
 pfu DENV was mixed with 800nmol of DiD (Invitrogen) in 
DMSO (final DMSO concentration <2.5%). After 30 min free DiD was removed by 
gel filtration on Sephadex G-25 column (Amersham Biosciences) equilibrated in HNE 
buffer.  DiD-labeled DENV was stored at 4˚C and used within 24 hr. Summer Zhang 
performed the Alexa Fluor labeling of DENV. For Alexa Fluor labelling, 
approximately 9x10
8
 pfu DENV was labeled with 100µM of Alexa Fluor 594 
succinimidyl ester (Molecular Probes, Invitrogen) for 1hr at room temperature. The 
labelling reaction was then stopped by adding 1.5M hydroxylamine, pH 8.5 and 
incubated at room temperature for 1hr. The excess dye was then removed by gel 
filtration on Sephadex G-25 column. AF594-DENV was stored in 100ul aliquots at -
80°C, re-titrated by plaque assay and tested for fluorescence using 
immunofluorescence assay on Vero cells before use in experiments. 
 
2.12 Visualization and quantification of DiD-virus uptake.   
Neutralizing concentrations of h3H5/human sera were incubated with DiD-labeled or 
AF594-labeled DENV for 1hr at 37˚C before adding to THP-1 (moi 10). Cells were 
then subjected to 20min synchronization on ice, followed by 30min infection at 37˚C 
and fixed with 3% para-formaldehyde (pFA) for 30min in ice. Following which, cells 
were subjected to cytospin at 800rpm for 3min. After washing with PBS at 4ºC, 
permeabilization buffer (0.1% saponin in wash buffer) was added for 30min and cell 





Subsequently, cells were washed with wash buffer, and secondary antibodies anti-
mouse-Alexa488 and anti-human IgG-Cy3 were added and incubated for 45min at 
room temperature. Thereafter, cells were subjected to washing with wash buffer, PBS 
and then water, followed by mounting the slides with mowiol. Samples were viewed 
under a laser scanning confocal microscope (Leica TCS SP2) and co-localization 
studies performed by using 488nm, 514nm and 633nm laser to excite Alexa488, Cy3 
and DiD respectively. 
 To assess by flow cytometry, cells were washed twice with PBS in 1% FCS 
after fixing with 3% pFA. Data acquisition was performed on FACSCanto flow 
cytometer. 
 
2.13 Sucrose gradient analysis of DENV immune complex sizes 
Sucrose gradient and dynamic light scattering was performed in collaboration with 
Hwee Cheng Tan and Summer Zhang. Sucrose gradient was formed by careful 
layering of 10-60 sucrose solutions (in HNE buffer) in 10% increments, starting with 
the densest at the bottom, in 13.5ml Ultra-Clear tubes (Beckman Coulter, Singapore). 
The gradient was allowed to linearize overnight at 4°C. Equal amounts of purified 
DENV were incubated with humanized antibodies at 3 or 100µg/ml h3H5 IgG or 
h3H5 Fab (h3H5 enzymatically digested to give only 1 arm of the Fab fragment) for 
1hr at 37°C. The samples were then carefully layered on top of the linearized 10-60% 
sucrose gradient, and centrifuged overnight at 25,000rpm at 4°C, in SW41Ti rotor for 
17hrs. Each gradient was then harvested in 0.25ml fractions from the bottom of the 
tube. Subsequently, viral RNA was extracted from each fraction and quantified by 
real-time PCR. The proportion of virus present in each fraction was then tabulated by 





The sucrose fraction that showed the highest virus genome copy number was 
identified as the peak fraction and subjected to dynamic light scattering to determine 
DENV immune complex diameter. 20µl of each fraction was loaded into Quartz 
cuvette for analysis by Zetasizer Nano S machine (Malvern Instruments, UK) at 37°C 
using 50% sucrose in HNE buffer as the dispersant. Data was then analysed using 
Zetasizer Nano software version 6.01. The diameter reports generated were average of 
more than 10 readings. 
 
2.14 Western blot. 
Cells were washed once in PBS and resuspended in lysis buffer containing 1% NP-40, 
150mM NaCl, and 50mM Tris, pH 8.0 in the presence of protease inhibitors (Sigma). 
After centrifugation, the cell lysates were exposed to 1x loading buffer and separated 
by SDS-PAGE. After transfer to polyvinylidene fluoride (PVDF) (Millipore), the 
proteins were detected with specific antibodies (Table 2-1) followed by addition of 
HRP-conjugated anti-mouse or HRP-conjugated anti-rabbit antibody (Table 2-1). 
Bands were visualized using enhanced chemiluminescence (Amersham) for 
development. 
 
2.15 Immunoprecipitation.  
Total cell extract (~100 μg) was incubated with mouse anti-Syk monoclonal antibody 
(4D10) at 4°C overnight and then with 50μl of Protein G–Sepharose (Pierce) for 2h. 







2.16 siRNA transfection of THP-1 and K562.  
Human FcγRIIB siRNA, FcγRIA, FcγRIIA, LILRB1 siRNA or AllStars negative 
control siRNA (Qiagen) duplexes (50nM) were incubated with DharmaFect2 
(Dharmacon) in serum-free media for 20min, and then added to cells at density of 2 x 
10
5 cells/ml. After 6hr incubation, cells were replaced with RPMI growth media for 2 
days to allow recovery. This was followed by a second round of siRNA transfection. 
Knockdown efficiency was determined by western blot. 
 
2.17 Overexpression in THP-1.  
FcγRIIB, LILRB1 and vector cDNA was purchased from Origene and transfected 
using Lipofectamine LTX
TM
 and Plus reagent
TM
 (Invitrogen) in accordance with the 
manufacturer’s instructions. Cells were subjected to two rounds of transfection and 
transfection efficiency was determined by western blot. 
 
2.18 Receptor blocking studies  
2x10
5
 cells/ml were pre-treated with 15µg/ml of anti-interferon alpha receptor 
(IFNAR), 10µg/ml of anti-LILRB1 or their respective isotype controls for 1hr at 4ºC. 
Subsequently, cells were washed once with maintenance media before adding h3H5-
opsonised DENV-2. 
 
2.19 Assessing surface monocytic marker expression 
Phenotypic analysis of the monocytic markers was performed with assistance from 
Nivashini Kaliaperumal in Singapore Immunology Network. THP-1, THP-1.2R and 
THP-1.2S were resuspended in staining buffer consisting of 10% Fetal Calf Serum 







well human FcγR block (eBioscience) at 1:10 was added and incubated for 25 
minutes on ice followed by a single wash with staining buffer. Subsequently, human 
monoclonal antibodies, anti-HLA-A,B,C/MHC Class I (W6/32) FITC (Biolegend); 
Anti-CD85j/ILT2 (GHI/75) FITC (BD Pharmingen); Anti-CD206 (19.2) PE (BD 
Pharmingen);  Anti-CD274/PD-L1 (MIH1) PE (BD Pharmingen); Anti-CD86 (FUN-
1) PE-Cy7 (BD Pharmingen); Anti-CD11b (ICRF44) PE-Cy7 (BD Pharmingen); 
Anti-HLA-DR/ MHC Class II (L243) APC (BD Pharmingen); Anti-CD11c (S-HCL-
3) APC (BD Pharmingen); Anti-CD80 (L307.4) AF700 (BD Pharmingen); Anti-
CD40 (5C3) AF700 (BD Pharmingen); Anti-CD14 (M5E2) Pacific Blue (BD 
Pharmingen); Anti-CD85k/ILT3 (ZM 4.1) PE (eBioscience); 7-AAD Viability 
Staining Solution and Anti-CD16 (CB16) eFluor®605NC (eBioscience) was used at 
previously optimized concentrations and incubated for 30 minutes on ice. Flow 
cytometry was performed with LSRFortessa™ cell analyzer (Becton Dickinson), 
acquired with BD FACSDiva Version 6.1.3 and analyzed using FlowJo 7.6.1. The 
specific median fluorescence intensity for each receptor was compared against its 
matching fluorescent minus one (FMO) control. Calibration was completed with 
SPHERO™ Rainbow Calibration Particles (Sphereotech Inc, Illinois, USA) to 
maintain consistency between experiments and to remove background fluorescence. 
Final values were expressed as milliequivalents of soluble fluorescence (MESF).  
 
2.20 Microarray analysis  
Following RNA extraction, microarray was performed at the Duke-NUS Genome 





Beadchips, according to manufacturer’s instructions. Data analysis was performed 
using Partek software and normalized against GAPDH. 
2.21 Interferon and drug treatment 
For interferon treatment, THP-1.2S was treated with 500 U/ml IFN-β (Millipore) 
30min after incubation with h3H5-opsonised DENV-2. ISG expression was assayed 
6hpi using real-time qPCR.  For piceatannol treatment, 2x10
5
 cells/ml of THP-1.2R or 
THP-1.2S were treated for 6hrs at indicated doses. h3H5-opsonised DENV-2 was 
added to cells at moi of 10. Cells were lysed 10min post-infection and proteins were 
eluted with SDS-PAGE loading buffer. Immunoblotting with anti-pSTAT-1 and anti-
STAT-1 (BD Biosciences) was performed as described above. Viral RNA and ISG 
expression was assayed 6hpi using qPCR. 
 
2.22 Co-immunoprecipitation 
Cells were incubated with h3H5-opsonised DENV-2 for 30 seconds or 10min at 37°C. 
Cells were washed twice with PBS and incubated 2hrs at 4°C with 0.75mM of 
chemical crosslinker DTSSP (Pierce). Stop solution (1M Tris, pH 7.5) was added to 
stop crosslinking and cells were lysed. 5ug of anti-LILRB1, isotype control antibody 
(Abcam) or h3H5 was incubated with lysate overnight at 4°C. Protein G-sepharose 
beads were washed with immunoprecipitation buffer (25mM Tris, 150mM NaCl, pH 
7.2) and incubated with lysate for 2hrs at 4°C. After washing, proteins were eluted 
with SDS-PAGE loading buffer and DENV E protein or LILRB1 was detected with 






2.23 ELISA to assess LILRB1 binding to DENV 
ELISA was performed with help from Zhang Qian. Purified viruses, E-protein, BSA 
or PBS were coated on MaxiSorp plates overnight at 4°C. After blocking with 5% 
skim milk for 2 hours, the plate was washed twice with PBS. Following which, the 
wells were incubated with various concentrations of LILRB1 protein (Origene) for 1 
hour at 37 °C and 1 hour at room temperature. Plates were then washed with PBS-T 
for 5 times before incubating with anti-LILRB1 antibody (Abcam) for 2 hours at 
room temperature. After which, the plates were washed 5 times and anti-mouse IgG 
HRP conjugated antibody was added for 1 hour at room temperature. After washing, 
TMB was added and stopped with 1M hydrochloric acid before visualizing at 450nm 
wavelength. 
 
2.24 Statistical analysis.  
Two-tailed unpaired Student t-test was used to determine if the difference in mean 
observed was statistically significant (P<0.05). All calculations were done using 


























 The results section is divided into 3 sections. Using labelled DENV, we 
examined the early interactions involved in antibody-mediated neutralization in 
monocytes (Section 3.1) and investigated how engagement of different FcγRs can 
affect the stoichiometric requirements for DENV neutralization (Section 3.2). Lastly, 
we identified the FcγR related signalling events in ADE of DENV infection of 



















Early interactions in antibody-mediated 








3.1.1 Homologous DENV serotypes are neutralized despite FcR-mediated 
phagocytosis but heterologous DENV serotypes are neutralized only when FcR-
mediated phagocytosis is inhibited. 
To explore the interactions involved in antibody-mediated neutralization in 
monocytes, early convalescent sera from patients with primary DENV infection was 
obtained. Confirmation of the primary infection status, along with the identification of 
the DENV serotype with which these patients have been infected, was carried out in 
the corresponding acute serum sample. The results are shown in Table 3-1. Using the 
PRNT on BHK cells, cross-reactive antibodies were detected in these early 
convalescent sera (Table 3-1), which is consistent with previous findings (Beltramello 
et al., 2010, Dejnirattisai et al., 2010). Besides BHK cells, these sera were also able to 
neutralize the four DENV in FcγR-expressing THP-1, although at different 
neutralization titers (Figure 3-1).  
We next investigated the intracellular events of DENV immune complexes in 
THP-1 cells using DiD-labelled DENV. DiD is a lipophilic fluorescent probe, the 
signal of which is quenched when present on the virus at high concentration. However, 
upon FcγR-mediated phagocytosis, DiD diffuses into the phagosomal membranes and 
the corresponding dequenching of fluorescence signal allows for the detection and 
visualization of DiD in cells (van der Schaar et al., 2007a, van der Schaar et al., 2008). 
Distinct differences in the early events were observed when DENV was reacted with 
highest dilution of serum that resulted in complete virus neutralization (hereafter 
referred to as the DENV immune complex) in THP-1 (Figure 3-2A). In a serum 
sample that completely neutralized DENV-1 and DENV-2, uptake of neutralized 





cytometry, when DENV-2 (homologous) instead of DENV-1 (heterologous) was used 
(Figure 3-2B). Confocal immunofluorescence indicated that the neutralized DENV-2 
immune complexes were co-localized to LAMP-1 compartments (Figure 3-2C). On 
the contrary, no subcellular trafficking of the neutralized DENV-1 immune complexes 
was observed (Figure 3-2C). These observations were also reproduced in a panel of 
sera from DENV-2 primary patients where uptake of the DENV immune complexes 
was observed only when DENV-2 but not other serotypes were used (Figure 3-3). 
Moreover, these observations were not limited to DENV-2. Uptake of DENV immune 
complexes was observed when convalescent serum samples from patients with 
primary DENV-1, DENV-3 or DENV-4 were reacted with the homologous but not 
the heterologous serotypes (Figure 3-4). Collectively, these results indicated that 
neutralization of homologous DENV serotypes can occur at levels that mediate uptake 
of immune complexes but neutralization of heterologous DENV serotypes occurs only 





















isolation IgM IgG 
      
3136 36 69 hours DENV-2 DENV-2 - - 
  17 days ND ND + + 
       
6583 34 17 hours DENV-2 DENV-2 - - 
  36 days ND ND + + 
       
3111 21 29 hours DENV-2 DENV-2 - - 
  21 days ND ND + + 
       
3598 30 11 hours DENV-2 DENV-2 - - 
  23 days ND ND + + 
       
3623 32 16 hours DENV-1 DENV-1 - - 
  19 days ND ND + + 
       
3927 37 39 hours DENV-3 DENV-3 - - 
  20 days ND ND + + 
       
2270 25 46 hours DENV-4 DENV-4 - - 
  20 days ND ND + + 
       
Table 3-1. Sera characteristics from different patients 
 
 
In the acute sera sample, RT-PCR and virus isolation confirmed the DENV serotype 
that the patient was infected with. ELISA (PanBio) was performed to detect for IgM 












Convalescent DENV-1 DENV-2 DENV-3 DENV-4 
Primary infection     
3136 Acute <40 <40 <40 <40 
 Convalescent 80 160 40 1280 
      
6583 Acute <40 <40 <40 <40 
 Convalescent <40 80 <40 320 
      
3111 Acute <40 <40 <40 <40 
 Convalescent 40 40 40 80 
      
3598 Acute <40 <40 <40 <40 
 Convalescent 80 40 <40 80 
      
3623 Acute <40 <40 <40 <40 
 Convalescent 80 40 <40 80 
      
3927 Acute <40 <40 <40 <40 
 Convalescent 40 <40 80 80 
      
2270 Acute <40 <40 <40 <40 
 Convalescent <40 <40 <40 1280 
Table 3-2. Plaque neutralization assay for patient acute and convalescent sera.  
 
PRNT70 <40 for all four DENV serotypes in acute sera indicates that these samples are 
primary sera. Convalescent sera may have PRNT70 titers for more than one DENV serotype, 
indicating presence of cross-neutralizing antibodies. These data were produced with help 
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Figure 3-1. Convalescent primary DENV-2 sera neutralize homologous and 
heterologous DENV serotypes at different dilutions. Neutralization of DENV-1 (red), -2 
(blue), -3 (purple), -4 (black) by DENV-2 infected convalescent primary patient sera. 
Neutralization profile was obtained from plaque titers observed following 72hrs post-
infection, and compared to virus only infection. Arrows indicate the serum dilutions required 






      
 
Figure 3-2. Convalescent primary DENV-2 human sera neutralize homologous serotypes at levels permissible for internalization but 
neutralize heterologous serotypes at levels that inhibit uptake. (A) Summary of method used to investigate early events of neutralized DENV 
immune complexes in THP-1 cells. (B) Percentage of internalized DiD-labeled DENV virus (DiD
+ 
cells) in THP-1 cells at 30 min post infection 
when in complex with convalescent serum (3136) at the respective neutralizing titers, analyzed by flow cytometry. Data are normalized against 
cells infected with only virus (without antibodies) to account for differences in uptake for different DENV serotypes. (C) Fate of neutralized 
immune complexes when 3136 is in complex with DENV-2 or DENV-1. LAMP-1 is green, DiD-labeled DENV is blue, and h3H5 is red. (Scale 
bar, 7.5 μm.) Data are represented as mean ± SD. **p  < 0.01. 
 
 






Figure 3-3. Convalescent primary DENV-2 human sera neutralize homologous serotypes at levels permissible for internalization but 
neutralize heterologous serotypes at levels that inhibit uptake. (A) Same analysis as described in Figure 3-2, but with three other 
convalescent primary DENV-2 sera (6583, 3111, 3598). Neutralization titers < 10 were not considered for this analysis.
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Figure 3-4. Convalescent primary human sera neutralize homologous DENV 
serotypes at levels that permit internalization, but not heterologous DENV. (Left 
panel) Neutralization of DENV-1 (red), -2 (blue), -3 (purple), -4 (black) by DENV-2 
infected convalescent primary patient sera. Arrows indicate the serum dilutions 
required to neutralize the viruses completely in THP-1 monocytes. (Right panel) 
Percentage of internalized DiD
+
 cells in THP-1 cells at 30min post-infection, when in 
complex with convalescent sera (3623, 3927, 2270) at the respective neutralizing 
titers, normalized against cells infected with their virus only, in the absence of 
antibodies. (C) Fate of neutralized immune complexes when serum is in complex with 
different virus serotype. LAMP-1 is labelled green, DiD-labelled DENV blue and 
h3H5 red.  Neutralization < 1:10 is not considered for analysis. Data represents mean 








3.1.2 Increasing antibody concentrations inhibits FcγR-mediated uptake of 
immune complexes 
The observation that neutralized viruses are phagocytosed and trafficked to the late 
endosome/lysosome compartments is consistent with the known function of 
monocytes in removing immune complexes from circulation. However, the inhibition 
of uptake of neutralized immune complexes with heterologous sera is intriguing. We 
observed that the neutralization of heterologous DENV serotypes appear to occur at 
lower dilutions of the convalescent sera than that needed for the homologous serotype 
(Figure 3-2, 3-3), suggesting that the inhibition of FcγR-mediated uptake could be 
affected by antibody concentration. However, early convalescent sera may also 
contain IgM antibodies that could complex with DENV without interaction with FcγR. 
To address this potential interaction, we titrated a serum from a volunteer who was 
infected with DENV-2 over 30 years ago, determined his neutralizing titer to DENV-
2 and fate in THP-1. At serum titers that completely neutralized DENV-2 infection in 
THP-1 (Figure 3-5A), we observed that lower serum dilution resulted in similar 
reduction of DiD-labeled DENV-2 uptake whereas increasing serum dilutions resulted 
in FcγR-mediated uptake of immune complexes (Figure 3-5B, 3-5C). Next, to reduce 
variability resulting from the use of different sera, we investigated the mechanism for 
the observed concentration dependent effects using the monoclonal antibody (mAb) 
3H5, which has been shown to be a serotype-specific antibody against the lateral 
ridge epitope of DENV-2 (Sukupolvi-Petty et al., 2007b, Gentry et al., 1982). As 
FcγR engagement is required for FcγR-mediated phagocytosis of immune complexes, 
we generated a mouse-human chimeric antibody of 3H5 (h3H5) consisting of mouse 
VH and VL sequences and human γ1 and κ constant sequences (Hanson et al., 2006). 





(Figure 3-6A). Complete DENV-2 neutralization was observed from 1.56µg/ml to 
400µg/ml of h3H5 (Figure 3-6B). At sub-neutralizing concentrations of h3H5, 
enhanced viral infection was observed to a greater extent after humanization into 
IgG1. As IgG4 has been shown to bind to FcγR with lower affinity (Bruhns et al., 
2009), reduced ADE of dengue infection was also observed after humanization to 
IgG4, indicating that the specific interactions with human FcγR were attained (Figure 
3-6B). Similar to what was observed with convalescent sera, the immune complexes 
were trafficked to LAMP-1 compartments at 30min post infection with 1.56µg/ml of 
h3H5 although increasing h3H5 concentration to 400µg/ml resulted in inhibition of 
uptake of immune complexes (Figure 3-6C). However, because DiD signal is 
quenched before fusion with cellular membranes, it is not possible to visualize DENV 
outside of the cell. To overcome this limitation, we labelled DENV with Alexa Fluor 
and demonstrated that presence of antibody-bound viruses outside THP-1 (Figure 3-
6D). Similar findings were also observed when primary monocytes were used (Figure 
3-6E), indicating that immune complexes form with neutralizing antibodies can be 











Figure 3-5.  Increasing sera titers inhibits immune complex internalization by 
THP-1. (A) Neutralization profile of DENV-2 convalescent serum against DENV-2 
in THP-1. Plaque titers following 72hrs post-infection are compared with virus only 
to determine neutralization profile. (B)  Percentage of internalized DiD-labeled 
DENV-2 virus (DiD+ cells) in THP-1 at 30min post uptake when complexed with 
different neutralizing dilutions of convalescent DENV-2 serum, analyzed by flow 
cytometry. Dashed line indicates DiD+ cells in the presence of DiD-labeled DENV-2 
only. (C) Subcellular localization of DENV-2, DENV-2 in complex with 1:8 serum, 
and DENV-2 in complex with undiluted serum in THP-1 cells. LAMP-1 is labelled 
green, DiD-labeled DENV-2 blue and h3H5 red. Data are represented as mean ± s.d. 









Figure 3-6. Increasing antibody concentration inhibits immune complex 
internalization by THP-1. (A) ELISA readout of mouse, human/mouse chimeric 
IgG1 or IgG4 at serial 2-fold dilutions. Purified DENV-2 was used for coating of 
plates. (B) Various concentrations of mouse monoclonal antibody 3H5 or 
human/mouse chimeric h3H5 IgG1 or IgG4 were incubated with multiplicity of 
infection 10 of DENV-2 before infecting THP-1 monocytes for 72 hours. Infection is 
monitored using plaque assay. Dotted line indicates infection in THP-1 in the absence 
of antibodies. Error bars display standard deviation of triplicate infections. (C) 
Percentage of internalized DiD-labeled DENV-2 virus (DiD
+
 cells) in THP-1 cells at 
30min post uptake when complexed with different neutralizing dilutions of h3H5, 
analyzed by flow cytometry. Dashed line indicates DiD
+
 cells in the presence of DiD-
labeled DENV-2 only. (D) Subcellular localization of DENV-2, DENV-2 in complex 
with 1.56µg/ml h3H5, and DENV-2 in complex with 400µg/ml h3H5 in THP-1 cells. 
LAMP-1 is labelled green, DiD-labeled DENV-2 blue and h3H5 red. (E) Subcellular 
localization of Alexa594-labeled DENV in complex with 400µg/ml h3H5. LAMP-1 is 
green, Alexa594-labeled DENV-2 is red and h3H5 is blue. Data are represented as 









3.1.3 Size of DENV immune complex is dependent on the concentration of 
antibody 
One possible explanation for the observed antibody concentration dependent 
inhibition of immune complex uptake is that excess antibodies competed with the 
immune complexes for FcγR. To test this possibility, DENV in complex with h3H5 at 
400µg/ml was compared with that at 1.56µg/ml but with addition of isotype control 
antibodies to give a total antibody concentration to 400µg/ml. The addition of isotype 
control antibodies did not inhibit internalization of DENV-2 (Figure 3-7A, 3-7B), 
indicating that the inhibition of FcγR internalization cannot be explained by 
competition for limited receptors by free antibodies. Alternatively, increasing 
antibody concentration could have cross-linked DENV, resulting in formation of viral 
aggregates. To test this hypothesis, we used a sucrose density gradient consisting of 
layers extending from 60% sucrose to 10% sucrose in 10% increments to separate 
immune complexes of different sizes. Equal volume fractions were removed from the 
bottom of each tube for quantitative PCR analysis to detect for DENV RNA; immune 
complexes in the earlier fractions would thus have greater density (Figure 3-7C). In 
addition, the size of aggregates in fractions that showed peak viral RNA copy 
numbers was determined using dynamic light scattering (Figure 3-7D). Consistent 
with previous observations that DENV is ~50nm in diameter, we found that the 
average diameter of DENV-2 in the experiment was 51.9 nm. Reacting 33.3 μg/mL of 
the Fab fragments of 3H5 Fab or 3μg/mL of h3H5 with DENV-2 did not result in 
significantly different particle sizes. However, with 100μg/mL of h3H5, peak DENV 
RNA copies shifted to fraction 9 (Figure 3-7C), corresponding to an increased 
immune complex size of 148.2 nm in diameter (Figure 3-7D). A similar increase in 





Figure 2A. When undiluted serum was used, the peak DENV RNA copies shifted 
significantly to the smaller fractions (Figure 3-7E), which corresponded with an 
increased immune complex size of 182.3 nm in diameter (Figure 3-7F). Collectively, 

















Figure 3-7. Inhibition of immune-complex internalization is not due to FcγR 
competition but due to increased immune-complex size. (A) Percentage of DiD
+ 
cells at 30 min post uptake when in complex with 400 μg/ml h3H5 or 1.56 μg/ml 
h3H5 with addition of 398.44 μg/mL of human isotype control. (B) Subcellular 
localization of DENV-2 complexed with 1.56 μg/mL h3H5 and with the addition of 
398.44 μg/mL human IgG1 isotype control. LAMP-1 is green, DiD-labeled DENV-2 
is blue, and human antibodies are red. (Scale bar, 7.5μm.) (C) Proportion of total viral 
RNA extracted from the various sucrose fractions. Proportion of viral RNA in each 
fraction was determined by dividing the viral RNA copy number in that fraction by 
the viral RNA copy number in the entire gradient. Shown are the moving averages of 
free virus and 33.3-μg/ml Fab fragments of h3H5 or virus in complex with 3 μg/ml 
h3H5 or with 100μg/mL h3H5 using qPCR. (D) Diameter of the immune complexes 
measured using dynamic light scattering in the respective sucrose fractions with peak 
viral RNA copy number. (E and F) Similar to C and D, but with 1:10 or undiluted 
serum. Data are represented as mean ± s.d. ** p < 0.01. Panels C-F were kindly 






3.1.4 Aggregation of DENV enables antibodies to cross-link the inhibitory 
FcγRIIB 
Given the increase in size when higher concentrations of antibodies were reacted with 
DENV, it is possible that the resultant larger viral aggregates enable antibodies to 
cross-link the inhibitory FcγRs which are expressed at lower levels on the cell 
membrane. One candidate is FcγRIIB, which has been shown to exert an inhibitory 
effect on FcγR-mediated phagocytosis (Tridandapani et al., 2002, Hunter et al., 1998). 
Because cross-linking of FcγRIIB has been previously shown to result in SHP-1 
phosphorylation that down-regulates phagocytosis (Huang et al., 2003), we tested for 
SHP-1 and SHIP-1 phosphorylation when DENV-2 was in complex with 1.56µg/ml 
or 100µg/ml of h3H5. Increased phosphorylation was observed when DENV-2 was in 
complex with 100µg/ml h3H5 (Figure 3-8A). To confirm that FcγRIIB is functionally 
involved in the inhibition of immune complex uptake, we knocked down its 
expression in THP-1 using siRNA. Reduction of FcγRIIB but not FcγRI or FcγRIIA 
(Figure 3-8B) resulted in significantly increased uptake of viral aggregates even with 
high h3H5 concentration (Figure 3-8C). DENV-2 remained neutralized despite 
presence of uptake in the FcγRIIB knockdown cells (Figure 3-8D).  
 Conversely, overexpression of FcγRIIB in THP-1 cells (Figure 3-9A) resulted 
in reduced uptake of DENV immune complexes across all neutralizing antibody 
concentrations (Figure 3-9B) and lower levels of infection when sub-neutralizing 
concentrations of h3H5 were used (Figure 3-9C). Overall, these results indicate that 
ligation of FcγRIIB occurs at antibody levels that form large viral aggregates, thereby 














Figure 3-8.  FcγRIIB is involved in the inhibition of immune-complex 
internalization of larger viral aggregates. (A) THP-1 cells exposed to media 
(mock), DENV-2 in complex with 1.56 μg/mL h3H5, and DENV-2 complexed with 
100μg/mL h3H5 30 min post infection. Cell lysates were immunoblotted with anti-
SHP-1, anti-SHIP-1,anti-phospho-SHP-1 (p-SHP-1) and anti-phospho-SHIP-1 (p-
SHIP-1). (B) THP-1 cells transfected with a control siRNA or siRNA against FcγRIIB. 
Cell lysates were immunoblotted with anti-FcγRIIB, anti-FcγRI, anti-FcγRIIA, and 
LAMP-1 antibodies. LAMP-1 served as a loading control. (C) Percentage of 
internalized DiD-labeled DENV-2 in THP-1 cells transfected with control siRNA or 
siRNA against FcγRIIB when in complex with various h3H5 concentrations. Dashed 
line indicates DiD
+
 cells in the presence of DiD-labeled DENV-2 only, without 
antibodies. (D) THP-1 cells subjected to mock transfection or transfected with 
FcγRIIB DNA. Cell lysates were immunoblotted with anti-FcγRIIB, anti-FcγRI, anti-















Figure 3-9.  Overexpression of FcγRIIB inhibits immune-complex internalization 
and infection (A) THP-1 cells transfected with FcγRIIB and immunoblotted with 
anti-FcγRIIB, anti-FcγRI, anti-FcγRIIA, and LAMP-1 antibodies. LAMP-1 served as 
a loading control (B) Percentage of internalized DiD-labeled DENV-2 in THP-1 cells 
with mock transfection or with transfected FcγRIIB DNA. (C) Plaque titers at 72 h 
post infection on cells with mock transfection or with overexpression of FcγRIIB. 
Dashed line indicates plaque titers in the presence of DENV-2 only, without h3H5. 
No significant differences between control and treated cells were observed with virus-
only infection. (D) Schematic of how presence of FcγRIIB (Purple) can inhibit 
internalization of viral aggregates by activating FcγRI (Black) or FcγRIIA (Blue). 







3.1.5 Dengue neutralization in the presence of phagocytosis distinguishes 
serotype-specific from cross-neutralizing antibodies with better accuracy than 
PRNT 
Our findings thus far suggest that neutralization of homologous DENV serotypes 
occur at levels that allow FcγR-mediated phagocytosis. Higher antibody 
concentrations resulted in formation of DENV aggregates that co-ligate FcγRIIB, 
resulting in inhibition of phagocytosis (Figure 3-8). However, neutralization of 
heterologous DENV serotypes appears to occur at lower serum dilutions, which 
corresponded with significantly reduced phagocytosis (Figure 3-2, 3-3). Hence, this 
suggests that the serotype of the infection can be determined by assessing for 
neutralization in the absence of FcγRIIB co-ligation in THP-1 monocytic cells. This 
knowledge will be important as long-lasting humoral immunity following DENV 
infection is directed at the homologous but not heterologous serotypes (Sabin, 1952a). 
 We took advantage of the known presence of cross-neutralizing antibodies in 
early convalescence following a primary DENV infection (Beltramello et al., 2010, 
Dejnirattisai et al., 2010), which would enable us to compare a serological 
determination of the serotype of infection with the virological findings in the acute 
sera and determine its accuracy, unequivocally, for this study. We designed an 
investigator-blinded test of early convalescent serum samples obtained from patients 
with virologically confirmed DENV infection. A schematic illustration of the study 
approach is shown in Figure 3-10. Human sera used in this study were obtained from 
the EDEN study as previously described (Low et al., 2006) and approved by the 
National Healthcare Group Domain Specific Review Board (DSRB B/05/013). These 
samples were from adult patients (age >21 years) who provided written informed 





included in this study had positive RT-PCR findings but negative anti-dengue IgG in 
the acute serum samples (obtained within 72 hours from illness onset) as measured by 
ELISA (PanBio). The presence of pre-existing anti-flavivirus antibodies such as those 
against Japanese Encephalitis virus, Yellow Fever and West Nile virus was not 
assessed although the ELISA would have detected cross-reactive antibodies from 
prior infection or vaccination with these viruses. A priori statistical calculation using 
Wilson’s approach for calculating two sided confidence intervals, indicated that a 
sample size of 30 would provide a proportion estimate of 0.9 with a pre-set 90% 
confidence interval width of less than 0.20 (0.77,0.96) (PASS © 2010 Software). 
Hence, by convenience sampling, 30 convalescent sera were selected and coded by a 
member of the laboratory (Angelia Chow) independent of the team that carried out the 
study. Subsequent studies were carried out by all other authors blinded to the findings 
in the acute sera. The selected sera were collected at a median of 18 days (minimum 
12 days, maximum 32 days) from illness onset. 
PRNT50 and DENV neutralization in THP-1 were carried out on the 
convalescent sera. In these experiments, DENV-1 (07K2402DK1), DENV-2 (ST), 
DENV-3 (05K802DK1) and DENV-4 (05K2270DK1) were used. We also reacted 
sera with DiD-labelled DENV (van der Schaar et al., 2007b), at dilutions where 100% 
neutralization of DENV was seen in THP-1 and performed confocal 
immunofluorescence microscopy to assess for FcR-mediated phagocytosis at 30min 
post-inoculation (Figure 3-10). The titer that mediates complete DENV neutralization 
in THP-1 was used as data in section 3.1.4 has suggested that this titer can potentially 
distinguish homotypic from heterotypic antibodies (Figure 3-3, 3-4). Complete DENV 





acute infection (Figure 3-10). The RT-PCR findings in the respective acute sera were 
un-blinded only upon completion of the serological analyses.   
Of the 30 convalescent samples, only 8 (26.7%) showed PRNT50 to a single 
serotype. Similarly, these 8 sera displayed neutralizing titers to a single serotype in 
THP-1, all of which neutralized DENV in the presence of FcγR-mediated 
phagocytosis (Table 3-3). Among the remaining 22 convalescent sera, the highest 
PRNT50 titer was consistent with the serotype detected by RT-PCR in the acute sera in 
15 cases (68.2%, 95% confidence interval (95% CI) 45.0% - 86.1%). In the 11 
samples where the highest PRNT50 titer was at least 4-fold or higher than those of the 
other serotypes, the highest PRNT50 titer was consistent with the serotype of the 
infection. However, in the other 11 of the samples that showed (i) identical titers to 2 
serotypes or (ii) only 2-fold difference between the highest and the next highest titer, 
only 4 (36%) were consistent with the serotype of the infection (Table 3-3).  
Using the highest dilution that mediated 100% DENV neutralization in THP-1, 
only 13 out of the 22 cases correctly identified the serotype of infection (59.1%, 95% 
CI 36.4% - 79.3%) (Table 3-3). Confocal imaging, however, clarified the serotype of 
the acute infection, where 20 out of the 22 cases (90.9%, 95% CI 70.8% - 98.9%) 
showed complete DENV neutralization in the presence of FcR-mediated 
phagocytosis (Table 2). Overall, the accuracy of PRNT50, 100% neutralization in 
THP-1 and confocal imaging were 76.7% (95% CI 57.7% - 90.1%), 70.0% (95% CI 
50.6% - 85.3%) and 93.3% (95% CI 77.9% - 99.2%), respectively. Figure 3-11 
summarizes the results from the three different methods used in our study by DENV 
serotype. None of our patients were infected with DENV-4. Our findings hence 













Figure 3-10. Workflow of a blinded study to determine ability to clarify dengue 
serotype of early convalescent sera. PRNT and 100% neutralization titers in THP-1 
were established for all 30 early convalescent samples. Next, the highest 
neutralization titer from PRNT50 or 100% neutralization in THP-1 was taken to 
indicate the serotype of infection. Based on neutralization titers that mediated 
complete neutralization of DENV, confocal immunofluorescence was performed to 
determine the presence or absence of co-localization of labeled antibody-virus 
complexes. Presence of co-localization of antibody-virus complexes with LAMP-1 
was taken to indicate the presence of serotype-specific antibodies (white arrows), 
while inhibition of FcγR-mediated phagocytosis was taken to signify the presence of 
only cross-reactive antibodies. Green - LAMP-1, Red - human IgG, Blue - DiD 









Figure 3-11. Accuracy of PRNT50 and 100% neutralization in THP-1 with or 
without observing for FcγR-mediated phagocytosis in identifying the serotype of 
the acute infection. (A) Percentage of patient samples predicted correctly for DENV-
1 (n=10), DENV-2 (n=6) and DENV-3 (n=14) using either PRNT50. 100% 
neutralization in THP-1 or observing for FcγR-mediated phagocytosis. Patient 
samples with only one neutralization titer are classified as homotypic (Grey bars) and 
samples with more than one neutralization titers are classified as heterotypic (White 
bars). In brackets are percentages in which the serotype determined serologically 
correlated with the DENV serotype detected by RT-PCR in the respective acute 
serum samples. 
  






Table 3-3. Correlation of PRNT50, 100% dengue neutralization in THP-1 and 





    No. of sera correlated with serotype of infection 
  
No. of early 





Homotypic 8 8 8 8 
Heterotypic 22 15 13 20 





















3.2.1 FcγRI ligation is required for uptake of neutralized DENV immune 
complexes 
Data shown in the previous section indicated that h3H5 and serotype-specific 
antibodies can neutralize at levels that allow FcγR-mediated phagocytosis in THP-1 
(Figure 3-5, 3-6). Indeed, time-course studies reveal that DENV immune complexes 
are trafficked to LAMP-1 compartments as early as 30min post-infection (Figure 3-
12). When compared to K562 which expresses FcRIIA but not FcRI, a 4-fold 
increase in h3H5 concentration was required for complete DENV-2 neutralization 
(Figure 3-13A). Moreover, immunofluorescence microscopy with DiD-labelled 
DENV showed that at these antibody concentrations, FcγR-mediated phagocytosis 
was inhibited, as indicated by reduced DiD fluorescence in both flow cytometry 
(Figure 3-13B) and immunofluorescence microscopy (Figure 3-13C). These 
observations indicated that in K562 but not THP-1, the h3H5 concentration required 
for complete DENV neutralization may occur at levels where DENV aggregates are 












Figure 3-12.  DENV immune complexes can be neutralized intracellularly in 
THP-1. Time-course analysis (10min, 30min and 60min) of DENV-2, when in 
complex with neutralizing levels of h3H5 (1.56µg/ml). Green is LAMP-1, blue is 
DiD-labelled DENV-2 and red is h3H5 antibody. Arrows indicate the presence of co-







Figure 3-13. DENV immune complexes are neutralized in K562 by inhibition of 
uptake. (A) Neutralization profile of h3H5 against DENV-2 in THP-1and K562. 
Plaque titers following 72hrs post-infection are compared with virus only to 
determine neutralization profile. (B) Percentage of internalized DiD-labeled DENV-2 
virus (DiD
+
 cells) in THP-1 and K562 at 30min post uptake when complexed with 
neutralizing concentration of h3H5, analyzed by flow cytometry. (C) Localization of 
DENV-2 immune complexes in THP-1 and K562 at neutralizing concentration of 
h3H5.Green is LAMP-1, blue is DiD-labelled DENV-2 and red is h3H5 antibody. 








3.2.2 FcγR-mediated phagocytosis following FcγRIIB knockdown 
The observed co-incidence of increased h3H5 concentration for complete 
neutralization of 10 MOI of DENV-2 with reduced FcγR-mediated phagocytosis 
raises the possibility that entry through the FcRIIA pathway could require an even 
higher concentration of antibody to prevent infection. To test this possibility, the 
expression of FcRIIB was knocked down using siRNA (Figure 3-14A). With 
reduced FcRIIB expression, levels of intracellular DiD-labeled DENV-2 increased 
(Figure 3-14B, 3-14C). However, no further increase in h3H5 antibody concentration 
was observed for complete DENV neutralization compared to scrambled siRNA 
control, suggesting that the stoichiometric requirement for DENV neutralization is 














Figure 3-14. FcγRIIB ligation inhibits uptake of neutralized DENV immune 
complexes in K562. (A) K562 transfected with a control siRNA or siRNA against 
FcγRIIB. Cell lysates were immunoblotted with anti-FcγRIIB and LAMP-1 
antibodies. LAMP-1 served as a loading control. (B) Localization of neutralized 
DENV-2 immune complexes in K562 treated with either siRNA control or siRNA 
against FcγRIIB at 30min post-infection. Green is LAMP-1, blue is DiD-labelled 
DENV-2 and red is h3H5 antibody. (C) Percentage of internalized DiD-labeled 
DENV-2 virus (DiD
+
 cells) in K562 treated with either siRNA control or siRNA 
against FcγRIIB. (D) Neutralization profile of h3H5 against DENV-2 in K562 treated 
with either siRNA control or siRNA against FcγRIIB. Data are represented as mean ± 








3.2.3 Preferential engagement of FcγRI in monocytes results in neutralization 
of DENV immune complexes.  
The above experiment had compared the h3H5 concentration requirement in two 
different cell lines although both were derived from monocytes. To confirm the 
increased antibody concentration requirement for complete DENV neutralization in 
the absence of FcγRI, we knocked down FcγRI in THP-1 and determined the 
stoichiometric requirement for DENV neutralization. Consistent with observations in 
K562, knockdown of surface FcγRI expression (Figure 3-15A) resulted in an increase 
in h3H5 concentration needed for DENV-2 neutralization (Figure 3-15C). In contrast, 
knockdown of surface FcγRIIA expression in THP-1 (Figure 3-15B) resulted in a 
reduced h3H5 concentration for DENV neutralization (Figure 3-15C). Moreover, 
knockdown of FcγRIIA but not FcγRI also resulted in significant reduction in plaque 
titers (Figure 3-15D). Together, these results suggest that FcγRI plays an important 
role in the clearance of antibody-opsonised DENV following neutralization.  
Given the significant difference in the antibody concentration requirement for 
DENV neutralization when FcγRI is engaged instead of FcγRIIA, we next examined 
how the former receptor is preferentially engaged in cells that express both receptors.  
Indeed, FcγRI is known to have a greater affinity for IgG than FcγRIIA (Bruhns et al., 
2009).  To observe if THP-1 cells preferentially phagocytize h3H5-opsonised DENV 
with FcγRI, we took advantage of Alexa Fluor labeling of DENV (Zhang et al., 2010). 
After synchronization of cells with DENV opsonised with neutralizing or sub-
neutralizing concentrations of h3H5, including a virus only control, we fixed and 
sorted the cells to remove the cells that had not phagocytosed the labelled DENV.  
The remaining cells were affixed on glass slide and examined under 





localization of DENV, FcγRI and LAMP-1 could be observed at 120 minutes after 
synchronization between antibody-opsonised DENV and THP-1 cells. This co-
localization was evidently weaker with FcγRIIA.  At sub-neutralizing concentrations 
of h3H5, however, no difference was observed between the co-localization of Alex-
Fluor labelled DENV, either FcγRI or FcγRIIA, with LAMP-1 (Figure 3-16B). As 
expected, no co-localization between either FcγR was observed with DENV only 
infection.  
In addition to the co-localization with DENV, Figure 3-15 also indicated that 
FcγRI was clustered to a single pole on the cell.  A recent study has shown that 
clustering of FcγRI facilitated uptake of immune complex through this receptor (van 
der Poel et al., 2011). We thus tested if this could also explain our observation.  
DENV immune complexes and FcγRI were visualized at 15min, 30min, 60min and 
120min after synchronization with cells. 5 cells were selected at random and a 
constant area on the cell was selected to evaluate the intensity of FcγRI/ FcγRII using 
the Zen software for confocal. We observed a significant increase in the intensity of 
FcγRI but not FcγRIIA after 120min (Figure 3-17). These findings therefore 
demonstrate that neutralizing but not sub-neutralizing concentration of h3H5 was able 











Figure 3-15. FcγRI engagement increases stoichiometric requirement for dengue 
neutralization in monocytes. (A) Surface expression of FcγRI when treated with 
either siRNA control or siRNA targeted against FcγRI, as determined by flow 
cytometry. (B) Surface expression of FcγRIIA when treated with either siRNA 
control or siRNA targeted against FcγRIIA. (C) Neutralization profile of siRNA 
control, siRNA  FcγRI or siRNA FcγRIIA knock-down cells, after 72hrs post-
infection (D) Plaque titers of siRNA control, siRNA  FcγRI or siRNA FcγRIIA 
knock-down cells after 72hrs post-infection. This figure is done in collaboration with 













Figure 3-16. Preferential engagement of FcγRI occurs during neutralization of 
DENV immune complexes. (A) Localization of DENV-2 immune complexes or 
DENV-2 (Green) with respect to FcγRI (Red), FcγRII (Blue) or LAMP-1 (Red) at 
120min post-infection. Immune complexes are either formed with neutralizing or sub-
neutralizing concentration of h3H5. An inset is indicated on the right to magnify the 
localization of the immune complexes. (B) Percentage co-localization with FcγRI and 
FcγII when exposed to DENV-2 in complex with neutralizing or sub-neutralizing 
concentration of h3H5. Data are represented as mean ± s.d. Figure is kindly provided 







Figure 3-17. Increased clustering of FcγRI but not FcγRII occurs during 
neutralization of DENV immune complexes. (A) Localization of neutralized h3H5-
DENV-2 immune complexes (Green) with respect to FcγRI (Red), FcγRII (Blue) or 
LAMP-1 (Red) at 15min, 30min, 60min and 120min post-infection. (B) Intensity of 
FcγRI and FcγRII in the cell after 15min, 30min, 60min and 120min exposure to 
neutralized h3H5-DENV-2 immune complexes. Values are obtained by Zen confocal 
















Regulators of FcγR-signalling in 
antibody-dependent enhancement of 








3.3.1 Isolation of two THP-1 subclones with increased uptake of dengue 
immune complexes 
We have observed in the above two sections that only ~5% of THP-1 show uptake of 
h3H5-opsonised, DiD-labelled DENV (Figure 3-18A). This led us to hypothesize that 
the low rate of FcR-mediated phagocytosis is due to genetic heterogeneity in THP-1, 
either through the method in which it was derived (Tsuchiya et al., 1980) or through 
the genetic instability resulting from aneuploidy (Sheltzer et al., 2011). Using limiting 
dilution and in vitro expansion, we obtained subclones that were screened for 
increased phagocytic rates of DENV immune complexes. Out of ~50 subclones 
sampled, we identified two (labelled as THP-1.2R and THP-1.2S) that showed 
increased uptake of h3H5-opsonised DENV compared to the original THP-1 (Figure 
3-18B). A panel of monocyte surface markers was used to characterize these two 
subclones (Figure 3-19). Flow cytometry indicated that the expression CD11b, CD11c, 
CD14, CD16, CD32 (FcγRII), CD40, CD64 (FcγRI), CD80, CD86, CD206, CD274, 
MHC-I and MHC-II were similar in THP-1.2R and THP-1.2S. An identical HLA 
haplotyping finding confirmed that both subclones were derived from THP-1 and was 









Figure 3-18. Generation of THP-1 subclones (THP-1.2R, THP-1.2S) that show 
enhanced uptake of immune complexes. Percentage of internalized DiD-labeled 
DENV-2 30min post-infection when in complex with different concentrations of 
h3H5, ranging from ADE to neutralization conditions in THP-1. (B) Percentage of 
internalized DiD-labeled DENV-2 30min post-infection under ADE conditions in 









Figure 3-19. Characterization of THP-1.2R and THP-1.2S. Flow cytometry analysis of THP-1, THP-1.2R and THP-1.2S stained with 







Figure 3-19. Characterization of THP-1.2R and THP-1.2S. Flow cytometry analysis of THP-1, THP-1.2R and THP-1.2S stained with 






Table 3-4. HLA haplotyping for THP-1, THP-1.2R and THP-1.2S. 
Name of cell 
line HLA-A HLA-A' HLA-B HLA-B' HLA-DR HLA-DR 
 
THP-1.2R 02G1 - 1511 - 0101/18/20/24 1501/02/05/07 
 
THP-1.2S 02G1 - 1511 - 0101/18/20/24 1501/02/05/07 
 
THP-1 02G1 - 1511 - 0101/18/20/24 1501/02/05/07 
Data is kindly provided by the laboratory of Emeritus Prof Chan Soh Ha. 





3.3.2 Two subclones of THP-1 with differential susceptibility to antibody-
dependent enhancement of dengue infection 
Despite similar rates of phagocytosis of the DENV immune complexes, THP-1.2S 
produced significantly higher DENV titers than THP-1.2R when infected with virus 
opsonised with enhancing dilutions of h3H5 (Figure 3-20A) or convalescent human 
serum (Figure 3-20B). Interestingly, no difference in virus titers was observed when 
non-opsonised DENV-2 was used to infect the subclones (Figure 3-20C). Besides 
DENV-2, higher DENV titers were also observed in THP-1.2S compared to THP-
1.2R when infected with other DENV serotypes opsonised with humanized 4G2 
monoclonal antibody (Figure 3-20D). Furthermore, significant differences in DENV 
genome equivalents could be observed as early as 6 hours post-infection, where 
DENV RNA copy numbers showed an increasing trend in THP-1.2S but a decreasing 
trend in THP-1.2R (Figure 3-20E). Gene expression analysis using both microarray 
and quantitative RT-PCR indicated that the ISGs were significantly up-regulated in 
THP-1.2R but not in THP-1.2S at 6 hours post-infection (Figure 3-21A). These 
included Myxovirus (influenza virus) resistance 1 (Mx1), Mx2, viperin and ISG20 
(Figure 3-21B), which are potent inhibitors of DENV replication in human cells 
(Jiang et al., 2010). These THP-1 subclones can thus serve as useful tools to dissect 







Figure 3-20. ADE of DENV infection differs in THP-1.2R and THP-1.2S. (A) 
Plaque titers of THP-1, THP-1.2R or THP-1.2S when infected with DENV-2 
opsonised with different concentrations of h3H5.  (B) Plaque titers of THP-1, THP-
1.2R or THP-1.2S when infected with DENV-2 opsonised with different serum 
dilutions. (C) DENV-2 only infection, in the absence of antibodies in THP-1.2R or 
THP-1.2S. (D) Peak enhancement titers for DENV-1, DENV-3 or DENV-4 (all at moi 
10) opsonised with h4G2 in THP-1.2R or THP-1.2S. (E) Viral RNA copy numbers in 
THP-1.2R or THP-1.2S at different times post-infection under ADE conditions. Data 
are represented as mean ± s.d.  ** p < 0.01 
  








Figure 3-21. ISG upregulation differs in the THP-1 subclones. (A) Heat map of 
ISGs in THP-1.2R and THP-1.2S at 6h post-infection under ADE conditions. 
Different colours represent different levels of ISG upregulation in the subclones. (B) 
Validation of the microarray data by qPCR. Data are represented as mean ± s.d.        








3.3.3 IFN signaling pathway contributes minimally to ISG induction 
Since STAT-1 phosphorylation is necessary for ISG induction (Darnell et al., 1994), 
we quantified pSTAT-1 protein levels in THP-1.2R and THP-1.2S using western blot. 
As expected, levels of pSTAT-1 were higher in THP-1.2R than THP-1.2S as early as 
10 minutes after incubation with h3H5-opsonised DENV-2 (Figure 3-22A). Since the 
interferon Jak-Stat pathway has been shown to up-regulate STAT-1 and ISG, we 
examined the expression of IFN in the two subclones. We observed that the levels of 
IFN,  and  transcripts were not higher in THP-1.2R than THP-1.2S (Figure 3-22B). 
Furthermore, to confirm that the responses are IFN independent, we pre-treated THP-
1.2R with either anti-interferon alpha receptor (IFNAR) antibody at concentrations 
that inhibited IFN receptor signaling (Figure 3-23A) or isotype antibody control 
before infection with h3H5-opsonised DENV-2. No significant difference in ISG 
expression (Figure 3-23B) or DENV replication (Figure 3-23C) was observed when 
THP-1.2R was pre-treated with either IFNAR or isotype antibodies, indicating that 
the increase in pSTAT-1 levels and ISG expression was not mediated by secreted type 
I IFNs. The possibility that THP-1.2S had impaired IFNAR-mediated signaling was 
also excluded, as ISGs were significantly up-regulated in response to exogenous IFN 
(Figure 3-23D). Collectively, the data indicates that the differences in ISG expression 
upon the addition of antibody-opsonised DENV cannot be explained by differences in 









Figure 3-22. Early STAT-1 phosphorylation contributes to ISG induction, but 
differences are not due to IFN production. (A) Western blot of pSTAT-1, STAT-1 
and GAPDH levels in THP-1.2R and THP-1.2S at 10min post-infection under ADE 
or mock (h3H5 only) conditions. (B) Relative IFN-,  and  transcript levels in 









Figure 3-23. IFN signaling pathway contributes minimally to ISG induction. (A) 
ISG expression in THP-1.2R pre-treated with recommended concentration of anti-
IFNAR antibody or isotype antibody control before adding IFNα (500 U/mL). ISG 
expression in cells was quantified 6hrs later using real-time qPCR. (B) ISG 
expression and (C) Relative DENV RNA copy numbers at 6 hours post-infection 
under ADE conditions in THP-1.2R pre-treated with either anti-IFNR antibody or 
isotype antibody control. (D) ISG expression in THP-1.2S 6 hours post-infection 
under ADE conditions, with or without IFN- treatment. Data are represented as 








3.3.4 ISG induction following ADE of DENV infection is Syk-dependent 
Alternatively, phosphorylation of the ITAM following ligation of activating FcγRs by 
antibody-opsonised DENV could have led to the activation of Syk tyrosine kinase 
(Kiener et al., 1993) followed by STAT-1 to trigger ISG expression (Dhodapkar et al., 
2007, Tassiulas et al., 2004). This possibility is likely as ADE occurs at low antibody 
concentration where the inhibitory FcγRIIB is not co-ligated. Hence, we tested for 
levels of pSyk protein after 10 minutes incubation with h3H5-opsonised DENV-2 and 
observed that the level of pSyk protein was higher in THP-1.2R compared to THP-
1.2S (Figure 3-24A). To verify that Syk phosphorylation was an important regulator 
of the antiviral response observed in THP-1.2R, we treated THP-1.2R and THP-1.2S 
with piceatannol, a Syk-selective tyrosine kinase inhibitor. This resulted in a dose-
dependent reduction of pSTAT-1 levels (Figure 3-24B) and ISG expression (Figure 3-
24C), but a concomitant dose-dependent increase in DENV RNA copy numbers 
(Figure 3-24D) in THP-1.2R. In contrast, a smaller increase in DENV RNA copy 
numbers upon piceatannol pre-treatment in THP-1.2S was observed upon addition of 
h3H5-opsonised DENV. These findings indicate that Syk phosphorylation triggered 








Figure 3-24. ISG induction following ADE of DENV infection is Syk-dependent. 
(A) Western blot of pSyk and Syk levels in THP-1.2R and THP-1.2S under ADE 
conditions for 10min, using immunoprecipitation with Syk antibody. (B) Western blot 
of pSTAT-1, STAT-1 and GAPDH levels, and (C) ISG expression in DMSO- and 
piceatannol-treated THP-1.2R under ADE conditions. (D) Fold change in DENV 
RNA copy numbers in THP-1.2R and THP-1.2S pre-treated with DMSO or 








3.3.5 ISG induction following ADE of DENV infection can be attenuated by 
increased SHP-1 phosphorylation 
Smaller increase in DENV RNA copy numbers upon picetannol pre-treatment (Figure 
3-24D) and the reduced ISGs (Figure 3-21) upon addition of h3H5-opsonised DENV 
collectively suggest that Syk protein activation by FcγR is inhibited in THP-1.2S. As 
activating FcγR signals through ITAM, we postulate that a receptor with an ITIM 
cytoplasmic tail could be recruited by DENV to inhibit Syk and STAT-1 activation 
(Steevels and Meyaard, 2011). Examination of the gene expression data identified two 
such receptors that were differentially expressed in our subclones. Leukocyte 
immunoglobulin-like receptors-B1 (also known as CD85j or immunoglobulin-like 
transcript-2) and -B4 (LILRB1 and LILRB4) were found to be upregulated pre-
infection in THP-1.2S compared to THP-1.2R (Figure 3-25A). Flow cytometry 
analysis, however, showed that LILRB1 but not LILRB4 displayed higher expression 
on the cell membrane of THP-1.2S (Figure 3-25B). Based on median intensity, the 
surface expression of LILRB1 was significantly higher in THP-1.2S as compared to 
THP-1.2R (Figure 3-25C). Similarly, western blot analysis of the cell lysates of THP-
1.2S indicated higher expression of LILRB1 (Figure 3-25D). 
Since one of the effects of ITIM phosphorylation is the recruitment and 
phosphorylation of the tyrosine phosphatase SHP-1, we measured SHP-1 
phosphorylation in the two subclones (Fanger et al., 1998, Scharenberg and Kinet, 
1996). Higher pSHP-1 levels were found in THP-1.2S compared to THP-1.2R as 
early as 10 minutes after incubation with h3H5-opsonised DENV-2 (Figure 3-25E), 
suggesting that pSHP-1 dephosphorylated Syk and STAT-1 in THP-1.2S. However, 
the non-structural proteins of DENV, such as NS4B, could also inhibit STAT-1 





is too early for the DENV genome to be translated.  Nonetheless, we excluded this 
possibility by incubating THP-1.2S and THP-1.2R with h3H5-opsonised DENV-like 
particles that are devoid of the DENV genome (Purdy and Chang, 2005). Similar to 
whole virus, reduced STAT-1 phosphorylation and increased SHP-1 phosphorylation 








Figure 3-25. ISG induction following ADE of DENV infection is attenuated by 
SHP-1 phosphorylation. (A) Relative expression levels of ITIM-bearing receptors in 
THP-1.2S and THP-1.2R determined by microarray. (B) Representative flow 
cytometry plots of LILRB1 and LILRB4 in THP-1.2R and THP-1.2S. (C) Median 
intensity values and (D) western blot of LILRB1 in THP-1.2R and THP-1.2S. (E) 
Western blot of pSHP-1, SHP-1 and GAPDH levels in THP-1.2R and THP-1.2S 
10min post-infection under ADE or mock (h3H5 only) conditions. (F) Western blot of 
pSTAT-1, STAT-1, pSHP-1, SHP-1 and GAPDH after incubation with DENV-2 











3.3.6 Antibody opsonised DENV co-ligates LILRB1 with activating FcR for 
enhanced DENV replication 
The observed differences in LILRB1 expression and pSHP-1 levels suggest that 
antibody-opsonised DENV ligates LILRB1 to downregulate the activating FcR-
mediated antiviral response for enhanced infection. As such, altering LILRB1 
expression in the THP-1 subclones should alter their ADE phenotype. Indeed, 
knocking down LILRB1 expression in THP-1.2S using siRNA resulted in reduced 
DENV replication compared to scrambled siRNA control (Figure 3-26A). Conversely, 
over-expression of this receptor in THP-1.2R resulted in increased DENV replication 
compared to an empty vector control (Figure 3-26B).  
That LILRB1 can downregulate antiviral response triggered by activating 
FcγR suggests that DENV can bind directly to LILRB1. Hence, we performed co-
immunoprecipitation using anti-LILRB1 as the capture antibody. DENV-2 E protein 
could be co-immunoprecipitated from infected cell lysates using anti-LILRB1 but not 
with isotype control antibodies after 30 seconds incubation (Figure 3-26C). This 
interaction was evidently weaker at 10 minutes post-infection, at a time when 
confocal microscopy images of DiD-labeled DENV-2 opsonised with enhancing 
concentration of h3H5 indicate that phagocytosis had already occurred (Figure 3-
26D).  Furthermore, using LILRB1 recombinant protein as the capture, we observed 
binding of LILRB1 to whole virus DENV-1-4 (Figure 3-26E). However, binding with 
the DENV recombinant E-protein was not observed (Figure 3-26F), indicating that 
LILRB1 binds to a quaternary structure epitope on the E protein that is only present 





That LILRB1 is a necessary co-factor for ADE also suggests that blocking 
these receptors could serve to inhibit secondary dengue infection. Indeed, 
pretreatment of primary monocytes derived of PBMCs from a healthy human 
volunteer with anti-LILRB1 antibodies before the addition of h3H5-opsonised 
DENV-2 resulted in significantly reduced DENV replication. Differences in DENV 
RNA copy numbers between primary monocytes treated with anti-LILRB1 antibody 
or isotype control antibody could be observed at 6 hours post-infection (Figure 3-
27A).  Similarly, the plaque titers of DENV after 72 hours of incubation were 
significantly lower in the primary monocytes treated with anti-LILRB1 antibody 
(Figure 3-27A). These observations were recapitulated with human convalescent 
serum (Figure 3-27B), with the other 3 DENV serotypes (Figure 3-27C) and with 
primary monocytes from 12 different individuals (Figure 3-27D). Collectively, these 
findings indicate that antibody-opsonised DENV co-ligates LILRB1 with activating 
FcR for effective ADE of DENV infection. A schematic to represent how this 


















Figure 3-26. Antibody opsonised DENV co-ligates LILRB1 with activating FcR 
for enhanced DENV replication. (A) Viral RNA expression determined in siRNA 
treated cells under ADE conditions. Knock-down of LILRB1 was assessed by western 
blot. (B) Viral RNA expression in LILRB1 or empty expression vector transfected 
cells under ADE conditions. Overexpression of LILRB1 was assessed by western blot. 
(C) Lysates of THP-1.2S incubated with h3H5 opsonised DENV-2 for 30s or 10min 
and immunoprecipitated with LILRB1, isotype control antibodies or no antibody 
capture and immunoblotted with h3H5 antibody. DENV-2 infected cell lysate before 
immunoprecipitation served as control for E protein detection. (D) Subcellular 
localization of DENV-2 opsonised with enhancing h3H5 concentration at 10min post-
infection in THP-1. LAMP-1 is labeled green, DiD-labeled DENV-2 blue and h3H5 
red. Arrow indicates presence of co-localization. (E-F) ELISA read-out (OD450) using 
different concentrations of LILRB1 recombinant protein as the capture. (E) BSA, PBS, 
DENV-1-4 virions and (F) DENV-1-4 recombinant E-protein is used to test for 
binding. Data are represented as mean ± s.d. * p < 0.05. Panels E-F are kindly 
















Figure 3-27. Antibody opsonised DENV co-ligates LILRB1 with activating FcR 
for enhanced DENV replication in primary monocytes. (A) Viral RNA and plaque 
titers in primary monocytes derived from PBMCs, infected under ADE conditions 
after pre-treatment with anti-LILRB1 or isotype antibody control. (B) Plaque titers in 
PBMCs infected with DENV-2 opsonised with enhancing levels of convalescent 
serum, after pre-treatment with anti-LILRB1 or isotype antibody control. (C) Plaque 
titers in primary monocytes infected with DENV-1,-3, -4 under ADE conditions after 
pre-treatment with anti-LILRB1 or isotype antibody control (D) Plaque titers in 
primary monocytes of different individuals infected with DENV-1, 2, 3, 4 under ADE 
conditions after pre-treatment with anti-LILRB1 or isotype antibody control. (E) 
Schematic diagram showing how antibody opsonised DENV co-ligates LILRB1 and 
activating FcRs for effective ADE. Data are represented as mean ± s.d. ** p < 0.01. 


























How DENV immune complexes interact with monocytes is poorly understood, even 
though it represents an important piece of the puzzle of how dengue pathogenesis and 
immunity interact. Although previous studies have made use of kidney cell lines, the 
understanding of these events are less well understood in human monocytes, the 
primary targets of dengue infection (Kou et al., 2008). Here, using THP-1 and human 
primary monocytes, we investigated how dengue immune complexes can result in 
neutralization or enhancement of dengue infection. The discussion will first highlight 
the two different modes of neutralization in monocytes: (i) by formation of viral 
aggregates which co-ligate FcγRIIB and therefore inhibition in uptake and (ii) by 
engaging FcγRI for intracellular neutralization of dengue immune complexes. Finally, 
the role of a newly identified co-factor LILRB1, which the dengue immune 
complexes bind and regulate FcγR-signaling in monocytes to result in ADE of dengue 






4.2 Viral aggregates co-ligate inhibitory receptor FcγRIIB to inhibit uptake 
of dengue immune complexes 
In our study, we have first explored the initial events following the introduction of the 
DENV immune complex to THP-1 monocytic cells using early convalescent sera. On 
average, these convalescent sera were obtained 22 days post illness onset (Table 3-1). 
Antibodies at this early convalescent period have been shown to exhibit broad cross-
neutralization activity against the DENV serotypes that only became more serotype-
specific with time (Beltramello et al., 2010, Dejnirattisai et al., 2010). Using such an 
approach, we observed two distinct patterns of virus neutralization. At the highest 
antibody titers that produced 100% DENV neutralization, homologous DENV 
serotypes were internalized by THP-1 and trafficked to the late endosome/lysosome 
whereas heterologous DENV serotypes were neutralized only at titers where FcγR-
mediated uptake was inhibited (Figure 3-2, 3-3). Although the uptake of neutralized 
DENV was expected, the inhibition of FcγR-mediated uptake of DENV or other viral 
immune complexes has not been previously described as a means of viral 
neutralization. Our data indicate that, in addition to blocking attachment or fusion, 
antibodies can also neutralize by forming large viral aggregates (Figure 3-6), which in 
turn cross-links FcγRIIB to inhibit phagocytosis (Figure 3-7, 3-8). This was observed 
with both h3H5 and human polyclonal antibodies in a convalescent serum sample. 
The aggregated viruses allow the resulting immune complex to be sufficiently large to 
cross-link FcγRIIB, resulting in activation of phosphatases such as SHP-1 and SHIP-1 
to down-regulate phagocytosis (Smith and Clatworthy, 2010).  
Much work has highlighted the role of FcγRIIB in many aspects of immune 
and inflammatory responses and variations of the gene have been shown to be 





erythematosus and rheumatoid arthritis. However, the role of FcγRIIB in the immune 
response to infection has not been studied extensively. Most work has involved 
Streptococcus pneumoniae, a Gram-positive bacterium that is a major cause of 
pneumonia (Clatworthy and Smith, 2004). In these studies, FcγRIIB-deficient mice 
have been shown to have improved FcγR-mediated phagocytosis of the antibody-
bound bacterium. Likewise, FcγRIIB deficiency is associated with an increased 
resistance to Staphylococcus aureus (Gjertsson et al., 2002) and Mycobacterium 
tuberculosis (Maglione et al., 2008) infection in mice. The only study that has 
examined the role of FcγRIIB in response to viral infection showed that FcγRIIB-
mediated inhibition of phagocytosis by dendritic cells was associated with reduced 
antibody and T-cell responses to human papilloma virus-like particles (Da Silva et al., 
2007). The involvement of FcγRIIB in virus neutralization is thus unique and shows 
that ligation of FcγRIIB impairs phagocytosis and antibody-dependent enhancement 
in monocytes. In addition, our observations may also explain previously reported 
observations of peak antibody titers following acute influenza or dengue infections 
being associated with transient reduction in the phagocytic activity of macrophages in 
experimental mouse models (Astry and Jakab, 1984, Chaturvedi et al., 1983). 
That cross-linking of FcγRIIB can inhibit antibody-dependent enhancement of 
DENV infection would suggest that, as long as an antibody can bind to an epitope in a 
manner that allows for the formation of concentration-dependent viral aggregates, 
DENV can be neutralized in vivo. If immunity were to be mediated by this 
mechanism alone, then antibodies would protect against all four DENV serotypes. 
However, epidemiological observations indicate that lifelong immunity is specific to 
the serotype with which a person has been infected. This suggests instead that, for 





do not form viral aggregates that cross-link FcγRIIB, a scenario expected as antibody 
levels wane following acute infection. In contrast, inhibition of uptake of 
heterologous serotypes by the early convalescent sera from patients with primary 
DENV infection was observed only at low serum dilutions. This process may be the 
reason why a person can be transiently immune to the remaining three serotypes of 
DENV following an acute primary DENV infection (Sabin, 1952a, Imrie et al., 2007). 
Further studies, however, would be needed to establish this notion.  
As differential expression of FcγRIIB can result in inhibition of ADE of 
dengue infection (Figure 3-8), polymorphisms in the FcγRIIB gene may potentially 
influence susceptibility of individuals to secondary infections. To date, associations 
between FcγRIIB and severe disease outcome has not been investigated. Two 
promoter haplotypes have been described which can influence FcγRIIB surface 
expression; the common -386G:-120T variant and the less common -386C:-120A 
variant, both of which can influence FcγRIIB surface expression (Su et al., 2004). 
There are seven other non-synonymous single-nucleotide polymorphisms (SNPs) 
identified in FcγRIIB, one of which involves a non-synonymous T-to-C transition 
within the transmembrane domain of FcγRIIB (FcγRIIBT232), leading to the exclusion 
of FcγRIIB from lipid rafts and reduced macrophage and B-cell responses (Floto et 
al., 2005). With these known polymorphisms, it would be interesting to investigate 
their effects on neutralization and enhancement of DENV infection. In addition, our 
findings suggest that agonists that up-regulate the expression of FcγRIIB may also 
inhibit ADE of dengue infection. One possible candidate involves the use of 
intravenous immunoglobulin (IVIG), which is composed of polyvalent IgG derived 
from more than a thousand blood donors. Previous studies have shown that IVIG can 





Tackenberg et al., 2009), although the exact mechanism of how this occurs have yet 
to be fully elucidated. Furthermore, IVIG contains sialylated IgGs which are anti-
inflammatory and can reduce pro-inflammatory cytokines such as TNFα, IL-1β and 
IL-6 produced during progression of DHF/DSS (Kaneko et al., 2006). These effects, 
together with increased FcγRIIB co-ligation due to enhanced expression, can reduce 
FcγR-mediated phagocytosis and release of pro-inflammatory cytokines to restrict 
disease from progressing to severe dengue. At present, there is limited evidence 
documenting the effectiveness of IVIG in treatment of DHF/DSS (Rajapakse, 2009). 
Hence, well-designed randomized controlled trials will be useful to investigate the 
beneficial effects of IVIG in life-threatening manifestations of dengue.  
Our demonstration that antibodies aggregate viruses also raises several 
unexplored questions. In addition to interacting with FcγRs directly, immune 
complexes can also bind to complement components and interact with complement 
receptor 1 (CR1) on red blood cells in vivo. The determinants of the outcome of the 
simultaneous interaction between DENV immune complexes and the CR1 receptor 
along with the various types of FcγR on macrophages in the liver and spleen are 
unknown. Even if phagocytosis was not inhibited in this interaction, it would be 
interesting to determine if aggregation of DENV could sufficiently reduce the 
stoichiometric requirement for virus neutralization by reducing the epitopes available 







4.3 Assessment of FcγR-mediated phagocytosis to distinguish protective 
humoral immunity from cross-reactive immune response 
Using THP-1, we had observed that convalescent serum could neutralize the 
homologous serotypes in the presence of FcγR-mediated phagocytosis whereas 
heterologous serotypes are only neutralized at levels that inhibit uptake through 
FcγRIIB co-ligation. This approach was shown to be useful to determine the serotype 
of the infection and to assess the efficacy of vaccination to each of the four DENV 
serotypes (Table 3-3). As the tetravalent formulation of candidate dengue vaccines 
would elicit pan-dengue antibodies, clarifying whether these antibodies are able to 
neutralize each of the four DENV serotypes in the presence of FcγR phagocytosis, 
similar to antibodies generated following an acute infection, could inform on whether 
vaccination is likely to result in long-term serotype-specific immunity. 
From our observations, it is not evident why neutralization of heterologous 
serotypes could not occur in the presence of FcγR-mediated phagocytosis. One 
possible reason is that cross-reactive antibodies require higher amounts of antibodies 
to fulfil the stoichiometric requirement for DENV neutralization compared to 
serotype-specific antibodies (Pierson et al., 2007) and these antibody concentrations 
coincide with that which aggregates DENV for FcγRIIB co-ligation. It is also possible 
that the cross-reactive antibodies to DENV antigens have lower binding affinities that 
are compromised in the low pH environment within phagosomes. Indeed, serotype-
specific antibodies appear to be more potent in DENV neutralization although cross-
reactive antibodies were more abundant in convalescent sera (de Alwis et al., 2012). 
Hence, we suggest that in addition to blocking specific ligand-receptor interactions 
for viral entry, antibodies must prevent viral uncoating during FcγR-mediated 





identifying suitable antibodies for therapeutic development (de Alwis et al., 2011, de 
Alwis et al., 2012, Teoh et al., 2012).  
Taken collectively, the data obtained in this thesis shows that virus 
neutralization in the presence of FcγR-mediated phagocytosis is serotype-specific and 












4.4 Preferential engagement of FcγRI during dengue neutralization results in 
uptake and neutralization of dengue immune complexes 
Although both FcγRI and FcγRIIA have been shown to be important in ADE of 
DENV infection, the role of these receptors in the uptake and removal of immune 
complexes in human monocytes is still largely unknown. Recent studies using COS-7 
cells have demonstrated that FcγRI-γ transfectants required relatively less antibodies 
to neutralize DENV as compared to FcγRIIA transfectants (Rodrigo et al., 2009). 
However, these experiments were carried out in COS cells transfected with either 
FcRI or FcRIIA while monocytes and macrophages express both receptors 
simultaneously. Here, using THP-1 cells, we show that FcγRI is primarily involved in 
the uptake and removal of DENV when in complex with neutralizing levels of 
serotype-specific antibodies. In the absence of FcγRI, immune complexes are 
neutralized at higher antibody concentrations, which in the case of K562 coincide 
with that which forms viral aggregates to co-ligate FcγRIIB and thus inhibit 
phagocytosis (Figure 3-13). Moreover, in the presence of both FcγRI and FcγRIIA, 
we observed a progressive increase in recruitment and aggregation of FcγRI but not 
FcγRIIA when exposed to neutralized DENV immune complexes (Figure 3-15, 3-16), 
highlighting the importance of FcγRI engagement in DENV neutralization. While the 
mechanism remains to be fully investigated, it is possible that stimulation of FcγRI 
induces rapid cytokine stimulation that results in increased binding of immune 
complexes (van der Poel et al., 2010). As FcγRI binds to immune complexes with 
higher affinity as compared to FcγRIIA and resides in lipid rafts (Beekman et al., 
2008), this may explain why neutralized DENV immune complexes preferentially 






 Recently, Dai et al. (Dai et al., 2009) proposed that FcγRI cross-linking can 
induce expression of proinflammatory mediators and is associated with trafficking 
immune complexes to antigen-processing compartments, which can be protective 
against virus infections (Holl et al., 2004). It is hence possible that preferential 
engagement of FcγRI can direct neutralized dengue immune complexes to 
compartments that results in DENV degradation and hence, unfavorable for 
replication. In agreement with the role of FcγRI and studies described by Rodrigo et 
al (2009), our findings demonstrated that preferential engagement of FcγRI but not 
FcγRIIA is important in the uptake and clearance of antibody neutralized DENV. Our 
findings point to the importance of FcγRI in DENV neutralization and suggest that 
FcγRI and FcγRIIA signal differently and traffic the phagosomes to different cellular 











4.5 LILRB1 in ADE of dengue infection 
At low antibody concentrations where ADE occurs, we have shown that the inhibitory 
FcγRIIB is not co-ligated. The ligation of the activating FcγRs by DENV opsonised 
with sub-neutralizing levels of antibody would thus induce the expression of ISGs 
that would hinder DENV replication. Indeed, using subclones of THP-1 which show 
increased uptake of immune complexes but with differing susceptibility to ADE of 
dengue infection, we observed that antibody-opsonised dengue can directly activate 
Syk and STAT-1 to result in induction of ISG (Figure 3-22A, 3-24). This up-
regulation of ISG is independent of IFN production (Figure 3-22B, 3-23), which is 
consistent with previous observations (Dhodapkar et al., 2007). In addition, we have 
identified another inhibitory receptor, LILRB1, which interacts with DENV immune 
complexes to recruit the phosphatase SHP-1 that dephosphorylates Syk and STAT-1 
and thus downregulate the immune responses mediated by activating FcγRs (Figure 3-
25). Reduced expression or blocking the interaction of LILRB1 with DENV immune 
complexes resulted in increased activation of Syk and STAT-1, thereby upregulating 
ISGs and suppression of DENV replication (Figure 3-26, 3-27). While an array of 
host and viral factors can influence disease outcome (Modhiran et al., 2010, Ubol et 
al., 2010, Chareonsirisuthigul et al., 2007, OhAinle et al., 2011), none can explain 
how antibody-opsonised DENV escapes the ISG expression expected following the 
ligation of activating FcR. Here, we show that co-ligation of LILRB1 with activating 
FcγRs provides DENV with a mechanism to overcome this antiviral response, 
allowing ADE of dengue infection to occur.  
LILRB1 is broadly expressed by monocytes, dendritic cells, B cells and in 





with human MHC class I molecules, negative signals delivered can inhibit NK and T-
cell killing (Colonna et al., 1997). Co-ligation of LILRB1 with activating FcγR has 
also been shown to result in overall reduction of tyrosine phosphorylation (Fanger et 
al., 1998). Our findings extend these observations to show that DENV interacts with 
LILRB1 and suppresses antiviral responses expected following the ligation of 
activating FcγRs by antibody-opsonised DENV.  
Besides dengue, the family of LILRs are also involved in the viral immune 
evasion of other viruses such as Human cytomegalovirus (HCMV), Human 
immunodeficiency virus type 1 (HIV-1) and Epstein Barr virus (EBV). At present, 
most work has involved HCMV, where the expression of the glycoprotein in unique 
long-18 (UL-18) can bind LILRB1 with high affinity (Yang and Bjorkman, 2008). 
Similar to our observations, UL-18 interaction with LILRB1 can trigger an inhibitory 
signaling pathway that limits anti-viral effector functions and monocyte activation 
(Borges and Cosman, 2000, Cosman et al., 1997). In addition, expression of UL-18 
can compensate for the down-regulation of MHC class I molecules of infected cells 
during HCMV infection, preventing NK cytotoxicity (Prod'homme et al., 2007). In 
virus-specific CD8
+
 effector T-cells observed during persistent HCMV and EBV 
infection, increased LILRB1 expression also correlated with reduced cytokine 
secretion and cytotoxicity of these cells (Antrobus et al., 2005, Saverino et al., 2000, 
Poon et al., 2005). Increased inhibitory immunoregulatory impulses have also been 
shown to result in impaired dendritic cell function, accelerating HIV-1 disease 
progression (Huang et al., 2009). Hence besides altering the antiviral responses 
expected upon ligation of activating FcγR, these observations suggest that DENV 
may also bind LILRB1 on other cell types for immune evasion. Further in vivo studies 





model, such as the humanized mouse, as the LILRB1 gene is deleted in laboratory 
strains of mice (Kubagawa et al., 1997). 
Our findings that dengue immune complexes can directly trigger Syk to 
activate antiviral responses and inhibit dengue replication raise several important 
questions. Besides intracellular signalling, Syk has been shown to be critical for 
FcγR-mediated phagocytosis and maturation of actin-rich phagocytic cups into 
phagosomes (Gasparrini et al., 2012, Majeed et al., 2001, Huang et al., 2006). In our 
findings, we did not observe a reduction in uptake when Syk kinase is inhibited by 
piceatannol (Figure 39). It is hence possible that, in the presence of LILRB1 co-
ligation, dengue immune complexes may be internalized and transported to non-
degradative compartments via a yet determined pathway. How inhibition of Syk 
signalling affects the fate of DENV aside from reduced ISG upregulation immediately 
following FcγR-mediated entry could thus be an interesting area for further 
investigation. 
The data obtained in this thesis also showed that unlike FcγRIIB co-ligation, 
LILRB1 co-ligation did not affect phagocytosis of DENV immune complexes (Figure 
3-23). One possible explanation could be that the two inhibitory receptors have 
distinct pathways for their inhibitory signalling. FcγRIIB is primarily associated with 
the recruitment of SHIP (Ono et al., 1996), although SHP-1 and SHP-2 have been 
reported to be associated with this receptor (Huang et al., 2003, D'Ambrosio et al., 
1995) whereas LILRB1 is primarily associated with SHP-1 or SHP-2 (Fanger et al., 
1998, Ketroussi et al., 2011).  Although both SHIP-1 and SHP-1 are potent inhibitors 
of ITAM triggered activation, the inhibitory signalling pathways triggered by SHIP-1 





As co-ligation of LILRB1 by dengue immune complexes inhibits signalling 
triggered by activating FcγRs, polymorphisms in the LILRB1 gene may influence 
DENV pathogenesis and disease susceptibility. Previous studies have shown that this 
gene is highly polymorphic (Kuroki et al., 2005) and can be alternatively spliced to 
produce soluble forms of LILRB1 (Jones et al., 2009). Hence, it would be of interest 
to investigate the role of genomic polymorphisms and splicing of LILRB1 in 
influencing susceptibility to secondary DENV infections. 
That LILRB1 is highly expressed in monocytes and dendritic cells (Lamar et 
al., 2010, Cella et al., 1999) also offers DENV ample opportunity to evade the early 
antiviral response, and blocking this receptor or its signalling molecules could thus 
serve as a therapeutic strategy for secondary DENV infection. Our findings also 
suggest that for reduced risk of ADE, vaccines could be designed to generate high 
titre of antibodies that bind to the epitope on DENV that interacts with LILRB1. This 
effort would be aided by a solving the structure of this virus-receptor interaction. 
Determining the structure of how DENV binds LILRB1 could thus be a fruitful area 
of research.  
In conclusion, we suggest that ADE of DENV infection occurs through the co-







4.6 Concluding remarks 
Our findings provide some fundamental insights into neutralization and enhancement 
of DENV infection in monocytes. We show that high concentration of dengue 
neutralizing or cross-reactive antibodies can form viral aggregates that co-ligate 
FcγRIIB to inhibit FcγR-mediated phagocytosis of DENV immune complexes in 
human monocytes. At antibody concentrations which do not aggregate DENV, 
serotype-specific antibodies, but not cross-reactive antibodies can neutralize DENV 
by preventing viral uncoating after FcγRI-mediated phagocytosis. This may be further 
influenced by preferential engagement of FcγRI instead of FcγRIIA as the former 
requires fewer antibodies for complete neutralization, possibly by targeting these 
immune complexes to late endosomal/lysosomal comparments for degradation. At 
sub-neutralizing levels of antibodies that are unable to prevent virus uncoating, ADE 
of DENV infection can occur. However, as engagement of activating FcγRs signal an 
antiviral response that inhibits viral replication, co-ligation of LILRB1 is necessary 
for suppression of antiviral responses necessary for DENV replication. A schematic to 
illustrate our findings are shown in Figure 4-1. Collectively, this thesis demonstrates 
the mechanistic roles of two inhibitory receptors, FcγRIIB and LILRB1, in 








Figure 4-1. Schematic of our findings. At higher antibody concentrations that form 
viral immune aggregates, inhibition of phagocytosis occurs as the lowly expressed 
FcγRIIB (Red) is also co-ligated. However, at lower antibody antibodies, viral 
aggregates are not formed, and opsonised DENV binds to activating FcγRs (Black), 
especially  FcγRI to result in FcγR-mediated phagocytosis. Whether the antibody-
opsonised DENV results in neutralization or infection is dependent on the ability of 
the antibody to inhibit virus fusion. Potent neutralizing homotypic antibodies are able 
to inhibit viral fusion, hence directing DENV immune complexes to late 
endosomes/lysosomes for degradation. However, sub-neutralizing antibodies are 
unable to inhibit fusion intracellularly, resulting in viral RNA release. In addition, to 
allow viral replication to occur, co-ligation of LILRB1 (Green) is required to suppress 





4.7 Future studies 
Our studies thus far suggest that the interaction of dengue immune complexes with 
LILRB1 is important to suppress the antiviral responses triggered by activating FcRs. 
It will hence be of interest to identify the epitopes on DENV which bind to LILRB1. 
This structural information could be useful for the development of vaccines that 
generate antibodies that not only prevent fusion but also block DENV from co-
ligating LILRB1. In brief, this can be performed by overexpressing and purifying the 
soluble portion of LILRB1 in mammalian cells before reacting them against DENV 
and analysed by cryo-electron microscopy. Moreover, the use of infectious clones can 
directly address if variations in amino acid sequence within these epitopes could 
directly influence dengue replication during ADE, which will be important for 
surveillance.  
Besides induction of ISGs, Syk has also been shown to be involved in 
modulation of actin dynamics and calcium signalling. It is hence possible that 
LILRB1 engagement and the resulting reduced Syk activation may direct and traffic 
dengue immune complexes to cellular compartments that escapes recognition by 
pattern recognition receptors. To address this, cells treated with piceatannol could be 
compared with appropriate controls to identify the trafficking dynamics and fate of 
the immune complex. Lastly, experiments are under way to elucidate how ISGs can 
be triggered by DENV only infection independent of FcR-signalling (Figure 3-22). 
Our preliminary data suggests that ISG induction during DENV infection is instead 
dependent on pattern recognition receptor RIG-I and to a lesser extent, via Syk 
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1. Cell culture medium 
1.1 Fetal bovine serum (FBS) 
Heat-inactivate at 56°C for 30mins  
Aliquot into 50ml Falcon tubes.  
Store at -20°C till further use. 
 
1.2 BHK-21 growth medium, 500ml 
5ml of L-glutamine (200nM, Gibco) 
5ml of sodium pyruvate (100mM, Gibco) 
5ml of Penicillin/Streptomycin (100X liquid, Gibco) 
50ml FBS 
Top up to 500ml with RPMI-1640 (Gibco) and filter-sterilize 
 
1.3 BHK-21 maintenance medium, 500ml 
5ml of L-glutamine (200nM, Gibco) 
5ml of sodium pyruvate (100mM, Gibco) 
5ml of Penicillin/Streptomycin (100X liquid, Gibco) 
10ml FBS 
Top up to 500ml with RPMI-1640 (Gibco) and filter-sterilize 
 
1.4 Vero growth medium, 500ml 
5ml of sodium pyruvate (100mM, Gibco) 
5ml of Non-essential amino acids (10mM, Gibco) 
50ml FBS 





1.5 Vero maintenance medium, 500ml 
5ml of sodium pyruvate (100mM, Gibco) 
5ml of Non-essential amino acids (10mM, Gibco) 
10ml FBS 
Top up to 500ml with Medium-199 (Gibco) and filter-sterilize 
 
1.6 THP-1 growth medium, 500ml 
5ml of HEPES (1M, Gibco) 
50ml FBS 
Top up to 500ml with RPMI-1640 (Gibco) and filter-sterilize 
 
1.7 THP-1 maintenance medium, 500ml 
5ml of HEPES (1M, Gibco) 
10ml FBS 







2.1 ELISA coating buffer 
0.212g sodium carbonate (Sigma) 
0.252g sodium bicarbonate (Sigma) 
Dissolve in 50ml deionized water, adjust pH to 9.66 and filter-sterilize. 
 
2.2 ELISA wash buffer (PBST) 
Add 500μl of Tween-20 to 1L of 1xPBS. 
 
2.3 ELISA blocking buffer (1%) 
Dissolve 0.5g skim milk in 50ml of 1x PBS. 
 
2.4 ELISA antibody diluents (0.5%) 






3. Virus labelling and immuno-assays  
3.1  HNE buffer, pH 7.4 
0.651g HEPES (Sigma) 
4.38g sodium chloride (Sigma) 
0.019g EDTA (Sigma) 
Top up with 500ml deionized water, adjust pH to 7.4 and filter-sterilize 
 
3.2 Wash buffer 
10ml FBS 
Top up to 1L with 1xPBS 
 
3.3 Permeabilization solution  
Dissolve 1g saponin (Sigma) in 1L of 1x PBS 
 
3.4 12% paraformaldehyde (pFA) 
Dissolve 12g of pFA (Sigma) in 90ml of deionized water.  
Adjust pH to 7.2 and top up to 100ml with 1x PBS. Filter-sterilize and store in -80°C 
in aliquots. 
 
3.5 3% pFA 






4. Plaque assay 
4.1  0.8% methycellulose overlay 
(A) 2 x RPMI 
Dissolve RPMI-1640 powder (Gibco) in 500ml deionized water 
10ml sodium bicarbonate (7.5%, Gibco) 




(B) 1.6% carboxy-methyl cellulose (CMC) 
Dissolve 8g of CMC (Calbiochem) in deionized water 
Autoclave-sterilize at 121°C, 20min 
 
Add 1 part of 2X RPMI (A) to 1 part of 1.6% CMC (B) in 50ml Falcon tubes. Shake 
vigorously to mix. Store at 4°C. 
 
4.2  0.5% crystal violet in 25% formaldehyde 
5g crystal violet (Sigma) 
676ml 37% Formaldehyde 






5. Western blot 
 
5.1 Lysis buffer for western blot 
4.383g sodium chloride 
5ml Nonidet-P40 buffer 
3.03g Tris 
Dissolve in 500ml with milli-Q water 
Adjust to pH 8.0 
 
Protease inhibitor (Sigma) added fresh at 1:100 
 
5.2 Lysis buffer for co-immunoprecipitation 
 
4.383g sodium chloride 
0.5ml Nonidet-P40 buffer 
3.03g Tris 
Dissolve in 500ml with milli-Q water 
Adjust to pH 8.0 
 










5.3 Immunoprecipitation buffer  
1.51g Tris 
4.383g sodium chloride 
Dissolve in 500ml with milli-Q water 
Adjust to pH 7.2 
 
5.4 10x SDS running buffer 
288g glycine 
60.4g Tris base 
20g SDS 
Dissolve in 2 liters with de-ionized water 
 
To use, dilute 1 in 10 to use at 1x SDS running buffer 
 




Top up to 1 liter with de-ionized water 
 
 
 
 
 
 
 
 
